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Introduction 1 
Introduction 
Projections of the number of cancer cases are valuable in setting priorities for prevention and in anticipating 
the demand for cancer services. Adequate health service planning, especially with regard to staff training and 
recruitment, and the development of long-term capital projects such as radiotherapy units, requires estimates 
of the likely future burden of cancer. 
This is the third set of projections of future cancer cases produced by the National Cancer Registry. Although a 
wide range of methods is available for projecting cancer incidence and mortality [1-8] we have, to a large 
extent, adhered to the methods used in previous reports [5, 9, 10], as they have been proven over time and 
also provide some continuity. 
This report presents  
1. Current trends in numbers of new cancers and incidence rates over the period 1994 to 2010. 
2. Estimates of the future number of cancer cases, at five year intervals from 2015 to 2040. 
These estimates are presented for all cancer types combined, both with, and without, the inclusion of 
non-melanoma skin cancers; and for 22 individual cancers or cancer groups. At least two sets of estimates 
are given for each cancer, based on different methodologies for projecting future trends in incidence. The 
expected number of treatments (for surgery, chemotherapy and radiotherapy separately) for each cancer 
type, based on 2010 treatment utilization patterns, is also provided for 2025. 
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1. Summary 
Cancer incidence data from the National Cancer Registry from 1994 to 2010 and population projections from 
the Central Statistics Office have been combined to estimate the number of new cancer cases expected in the 
years 2015, 2020, 2025, 2030, 2035 and 2040, as well as the number of first treatment episodes expected in 
2025. A number of different estimation methods were used. 
The total number of new invasive cancer cases (including non-melanoma skin cancer) is projected to increase 
by 84% for females and 107% for males between 2010 and 2040, based only on changes in population size and 
age distribution (demography). If trends in incidence since 1994 are also taken into account, the number of 
cases is expected to increase by between 86% and 125% for females (depending on the method of projection 
used) and by between 126% and 133% for males. The projected increases are a little less than those published 
by the Registry previously, mainly due to changes in the CSO population projections following the 2011 census. 
If non-melanoma skin cancer is excluded, the numbers are expected to increase by 81% for females and 108% 
for males, based on demography alone. If trends in incidence are taken into account the expected increase in 
incidence for females is 48-112% and for males 114%-128%. 
With the exception of leukaemia in males, the number of cancers is projected to increase for all sites between 
2010 and 2040 (Figure 1.1). The most rapidly increasing cancers in coming decades are expected to be those of 
skin—both melanoma and non-melanoma—in both sexes. Cancers of the upper gastrointestinal tract—
oesophagus, pancreas and hepatobiliary tract—are also expected to increase by over 100% by 2040.  
Of the other common cancers  
 cancers of the colon and rectum are projected to increase largely in line with demographic change, by 
120%-130% between 2010 and 2040;  
 lung cancer incidence is rising more rapidly in females than in males and by 2040 the rate is projected 
to increase by 136% in females (Nordpred) and 52% in males;  
 female breast cancer is difficult to project, due to recent short-term variations in incidence trends, but 
is expected to increase by about 130% between 2010 and 2040. However one HD model projects a 
much slower rate of increase for females; 
 future trends in prostate cancer rates are unclear; the HD models project an increase of 104% in new 
cases by 2040, while Nordpred projects an increase of 288%; the latter, which is based on the rapid 
increase in rate in the early 2000s, driven by PSA testing, seems implausible;  
 the models for cancer of the bladder and for leukaemia in males were heterogeneous, and future 
trends in these are difficult to project. 
Although demographic change will be the main factor driving an increase in cancer numbers, trends in risk 
factor prevalence will also have an impact. 40% of the total cancer risk in the UK population (44% in males, 
35% in females) has been attributed to five lifestyle factors—tobacco, diet, overweight/obesity, alcohol and 
low physical activity [11]. The attributable risks in Ireland are likely to be similar. Smoking prevalence in Ireland 
is high, although decreasing slowly, and more rapidly in males than females [12]. Obesity and overweight are 
increasing in both sexes, as is alcohol consumption (although there may have been a recent decrease in the 
latter) [13, 14]. Levels of self-reported physical activity are low, and have not changed appreciably in the last 
two decades [15]. Apart from changes in risk factor prevalence, the expansion of population-based screening 
for breast, cervical and colorectal cancers may also bring some transient increases in cancer incidence. 
Modelling the expected impact of all of these changes is beyond the scope of this report, but would be 
worthwhile.  
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The models project an increase of about 50% in cancer cases by 2025, and treatment numbers are expected to 
increase correspondingly. The total number of patients having cancer-directed surgery is projected to increase 
by 50%-55% between 2010 and 2025, the number having chemotherapy by 42%-48% and the number having 
radiotherapy by 32%-35%. These changes, combined with increasing survival, will inevitably increase the 
burden on the cancer services. With the ageing of the population, and improving life expectancy, the median 
age of cancer patients at diagnosis will increase. Cancers will be diagnosed in an older population, which will 
have different needs, and clear guidelines will be needed on the assessment and treatment of older patients. 
The growing availability and use of ever more sophisticated and expensive targeted therapy will contribute to 
better survival, but the high costs of these therapies, especially for advanced disease, will need to be balanced 
against other priorities in cancer care.  
The coming decades will challenge the Irish cancer services to reduce the burden of cancer and to improve the 
quality of care, in the face of changing lifestyles and an increasing and more complex cancer burden. These 
projections, in indicating the likely future burden of cancer in the absence of effective primary prevention, can 
quantify the benefits and cost savings from effective action to reduce cancer risk. They can also inform 
decisions on allocation of resources between prevention, early detection and treatment.  
Figure 1.1. Projected percentage increase in number of cancer cases 2010-2040, by cancer site and sex 
females males 
  
86%
48%
45%
41%
152%
77%
116%
108%
62%
46%
127%
30%
58%
31%
196%
175%
68%
235%
84%
34%
140%
83%
32%
125%
112%
65%
62%
113%
88%
117%
115%
90%
128%
148%
11%
153%
92%
136%
93%
98%
162%
123%
44%
172%
110%
74%
0% 50% 100% 150% 200% 250%
all invasive cancers
all invasive cancers excluding NMSC
bladder
brain and CNS
breast
cervix
colon
colorectal
corpus uteri
head and neck
hepatobiliary
Hodgkin's lymphoma
kidney
leukaemia
lung
melanoma of skin
non-Hodgkin's lymphoma
non-melanoma skin
oesophagus
ovary
pancreas
prostate
rectum
stomach
projected % change in numbers 2010-2040
HD model Nordpred model
133%
128%
33%
149%
156%
121%
66%
113%
44%
24%
-57%
72%
327%
83%
356%
160%
152%
104%
105%
27%
126%
114%
9%
30%
104%
93%
108%
155%
41%
124%
39%
52%
134%
62%
157%
112%
129%
288%
77%
59%
-100% 0% 100% 200% 300% 400%
projected % change in numbers 2010-2040
HD model Nordpred model
Methods 4 
2. Methods 
Three methods have been used in this report to project cancer numbers:  
1. demographic projections, which apply the average age-specific incidence rates for 2006-2010 to the 
future projected populations. These assume that there are no changes in the underlying incidence 
rates over time and therefore make the fewest assumptions; 
2. age-period methods, as described by Hakulinen and Dyba [5, 9, 10], which apply linear, non-linear and 
log-linear models to historical data;  
3. the Nordpred method, which uses a special version of the age-period-cohort model [8, 16] with a 
power link. 
Details of the application of these methodologies are given below. 
The advantages and limitations of cancer projections have been described in previous reports [17-19]. It is 
important to note that this report gives projections of current data into the future, and not predictions. To 
make predictions, we would require knowledge of trends in underlying risk, which are not available in most 
cases. 
2.1 Cancer sites 
Data were modelled for 24 invasive cancer sites or groups of sites, including all invasive cancers combined, 
with and without the inclusion of non-melanoma skin cancer (Table 2.1). 
Table 2.1. Cancer sites and groups of sites for which projections are presented in this report 
Cancer site ICD10 codes 
1. All invasive cancers C00-C96 
2. All invasive cancers, excluding non-melanoma cancer of skin C00-C43; C45-C96 
3. Head and neck C01-C14, C30, C31, C32 
4. Oesophagus C15 
5. Stomach C16 
6. Colon C18 
7. Rectum and anus C19-C21 
8. Liver, gallbladder and biliary tract C22-C24 
9. Pancreas  C25 
10. Lung  C34 
11. Melanoma of skin  C43 
13. Non-melanoma cancer of skin  C44 
14. Female breast  C50 
15. Cervix uteri  C53 
16. Corpus uteri  C54 
17. Ovary  C56 
18. Prostate  C61 
19. Kidney and renal pelvis  C64-C65 
20. Bladder  C67 
21. Brain and other central nervous system  C70-C72 
22. Hodgkin’s lymphoma  C81 
23. Non-Hodgkin’s lymphoma  C82-85 
24. Leukaemia C91-C95 
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2.2 Projected populations 
The cancer case projections are based on the population projections of the Irish Central Statistics Office (CSO) 
[20]. A number of future projections have been published simultaneously by the CSO, based on different 
assumptions regarding mortality, migration (M) and fertility (F). These give expected population numbers for 
each year 2015-2046, by five year age group and sex. 
Mortality rates are assumed to decrease, which will result in gains in life expectancy at birth from: 
 77.9 years in 2010 to 85.1 years in 2046 for males 
 82.7 years in 2010 to 88.5 years in 2046 for females. 
Two fertility assumptions were used: 
 F1: Total Fertility Rate to remain at the 2010 level of 2.1 for the lifetime of the projections 
 F2: Total Fertility Rate to decrease to 1.8 by 2026 and to remain constant. 
Four migration assumptions were used: 
 M0: No net migration 
 M1: Net migration returning to positive by 2016 and rising steadily thereafter to + 30,000 per annum 
by 2021  
o -19,100 annual average per annum in 2011/2016 .  
o +18,200 annual average per annum in 2016/2021 
o +30,000 per annum in 2021/2026 
o +30,000 per annum in 2026/2046. 
 M2: Net migration returning to positive by 2018 and rising thereafter to +10,000 per annum by 2021 
o -21,600 annual average per annum in 2011/2016    
o +4,700 annual average per annum in 2016/2021    
o +10,000 per annum in 2021/2026    
o +10,000 per annum in 2026/2046.    
 M3: Net migration remaining negative for the whole period    
o -25,100 annual average per annum in 2011/2016    
o -10,000 annual average per annum in 2016/2021    
o -5,000 per annum in 2021/2026.    
Eight different population projections, based on combinations of the above assumptions, have been published 
by the CSO: M0F1, M0F2, M1F1, M1F2, M2F1, M2F2, M3F1 and M3F2. The mortality assumptions are the 
same for all projections. The fertility assumptions, which will affect only the population aged under 30 years by 
2040, will have a minimal impact on numbers of cancer cases over the period studied, since cancer is 
predominantly a disease of the elderly. Projected 2015 to 2040 populations for the M0F1 assumptions are 
shown in Table 2.2. These project a 15% increase in the male population and a 14% increase in the female 
population between 2015 and 2040. The size of population change ranges from a fall of 20-22% in those aged 
35-49 to an increase of 170% in males and 298% in females aged over 85.The population aged over 70 is 
projected to increase by 136% (females) and 119% (males). 
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Figure 2.1 shows the differences between the projected 2015 and 2040 populations for the different 
assumptions. The largest 2015-2040 differences for all the assumptions are in the youngest age groups, which 
have the lowest cancer rates. For most ages over 50 the projections suggest a population increase of just over 
50,000 in each five-year age group. 
Table 2.2. Projected M0F1 populations 2015-2040 
  year 
age group 2015 2020 2025 2030 2035 2040 
females       
under 35 1132979 1133075 1149540 1171807 1188221 1205124 
35-39 184426 172136 140319 127681 139839 151300 
40-44 175829 181963 169860 138288 125762 137916 
45-49 160066 174680 180938 169041 137768 125378 
50-54 147690 159026 173707 180099 168450 137570 
55-59 129921 144970 156443 171163 177703 166374 
60-64 115227 125644 140733 152319 167029 173726 
65-69 100381 108949 119555 134586 146229 160832 
70-74 72554 91618 100472 111154 125932 137516 
75-79 51404 62153 79872 88812 99327 113507 
80-84 32847 38968 48760 64157 72727 82591 
85 and over  21934 29077 38112 50840 69712 87323 
males       
under 35 1118279 1102441 1109944 1130282 1146392 1162231 
35-39 189321 188471 150191 130754 140968 152580 
40-44 176948 188338 187549 149428 130075 140294 
45-49 159297 176926 188360 187649 149752 130519 
50-54 149751 158604 176234 187715 187099 149521 
55-59 131361 147937 156887 174493 186021 185529 
60-64 116252 128874 145415 154462 172006 183573 
65-69 101960 112553 125179 141613 150749 168167 
70-74 76655 96450 107069 119622 135834 145038 
75-79 59130 69363 88151 98669 110979 126743 
80-84 44026 49297 59000 76055 86173 97906 
85 and over  45278 52763 62305 76727 99929 123269 
 
Figure 2.1. Projected population increase 2015-2040, by age group and population growth model 
females males 
  
Figure 2.2 shows the impact of the different population assumptions on projected overall cancer numbers, 
assuming that incidence rates remain constant over the period (i.e. method 3, demographic projections, as 
described on page 2). As most of the difference between the models is in the population under 60, who have a 
low cancer incidence, the impact of using different population projections is small, 6-7% of the overall 
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expected numbers in 2040. The overall number of invasive cancer cases, based only on population change, is 
projected to increase from 28,400 in 2010 to between 54,700 and 58,200 in 2040. The M1 assumptions give 
the highest projected population in 2040, and consequently the largest number of new cancer cases, while the 
M3 assumptions give the lowest. Throughout the rest of this report we have used the M0F1 populations for 
making projections as these make the fewest assumptions and produce projected case numbers which are 
approximately midway between the lowest and highest estimates. 
Figure 2.2. Case projections based on projected populations, all invasive cancers 
females males 
  
2.3 Historic incidence rates 
Projections are based on the assumption that current trends in incidence will continue into the future. The 
precision of the model is greatest if a long prior period of observation can be used. Where possible, all years of 
data from the National Cancer Registry, beginning from 1994, were used. For the Hakulinen and Dyba (HD) 
models (method 1 on page 2), trends in age-standardised incidence rate for each cancer were tested for 
linearity over the period 1994-2010, using Joinpoint software [21].  Joinpoint was constrained so that changes 
in rate over periods less than five years were not modelled. For cancers with a linear trend in incidence rate 
over the full period 1994-2010, cancer rates over this period have been used to construct the model. For other 
cancers, the most recent linear trend in the historic incidence rate data (the base of projection) for each 
cancer site was fitted using four different HD models (see section 2.4), for each sex separately, where relevant. 
For Nordpred (method 2 on page 2), aggregated incidence data for three five-year periods were used: 1996-
2000, 2001-2005 and 2006-2010. This is the minimum number of periods which is possible with the Nordpred 
software. Demographic projections were based on the average age-specific incidence rates in the period 2006-
2010 inclusive. Details of the models fitted to the data, and the historic period used, are given in the 
corresponding chapter for each cancer site or combination of sites.  
Only invasive cancers are considered in this report, as trends in non-invasive cancers (predominantly in situ 
cancers) are largely dependent on screening activity rather than underlying risk, and so cannot be convincingly 
modelled. 
2.4 Model fitting 
1. Demographic projections 
Demographic projections were produced by applying the population projections to the average age-specific 
incidence rates for each age group (0-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and 
80+) for each cancer for the years 2006-2010. 
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2. Hakulinen/Dyba age-period methods  
Hakulinen and Dyba [5, 9, 10] propose four age-period models to fit and project incidence data. These are: 
Model 1.                      
Model 2.             
          
Model 3.             
        
Model 4.                        
 
where 
n= number of cases 
p=population at risk 
i=age group 
t=time period 
  is the intercept 
  the slope  
These models use single year of incidence data and calculate projected numbers of cases, age-standardised 
incidence rates and 95% confidence limits for both.  
Hakulinen/Dyba (HD) model 1 is a linear model, which assumes that the cancer incidence rate increases by a 
fixed amount () annually. It estimates a different slope () for each age-group i, which can give a better fit to 
the data when there are opposing trends for different age groups e.g. an increasing trend for older, but a 
falling trend for the younger, patients. 
Models 2 and 3 are log-linear models, which assume that the incidence rate increases by a fixed proportion () 
annually. Model 2 allows for a different slope () for each age-group i, whereas model 3 does not. These 
models provide larger estimates of future increase and smaller estimates of decrease than the linear model.  
Model 4 is a non-linear model, which gives estimates which are similar to those from Model 1. However, the 
estimates of increase or decrease are always less than for Model 1, and the difference between these models 
becomes more pronounced with increasing time and/or when the rate of increase is greatest. This model is the 
most conservative of the four and gives estimates which are closest to the assumption of no change in 
underlying trend (i.e. demographic change only). 
The model with the best fit, as judged by the scaled standard errors of the projections, was used for the 
projections for each site, with a few exceptions, which are described in the chapters for individual cancers.   
3. Nordpred  
The Nordpred software provides projections for a maximum of four future five-year periods, and does not give  
confidence intervals for the projections (although these may be calculated using computationally intensive 
bootstrap methods [22]). It fits a power age-period-cohort model, with a power coefficient of 0.2, to the 
historic trends, using a different slope parameter for each age group (0-34, 35-39, 40-44, 45-49, 50-54, 55-59, 
60-64, 65-69, 70-74, 75-79 and 80+). This model is intermediate in its assumptions between the HD linear and 
log models. The Nordpred software gives aggregate case numbers for the four five-year periods 2015-2019, 
2020-2024, 2025-2029 and 2030-2034. Projected numbers for the years 2015, 2020, 2025, 2030, 2035 and 
2040 were derived from these estimates by linear interpolation and extrapolation.  
The application of the four HD models, Nordpred and the demographic projections to the incidence rate of all 
cancers combined (ICD 10 C00-C96) from 2015 to 2040 is shown in Figure 2.3. For all cancers combined, the 
projections made by the four models are similar.  
As there is an upward trend in age-standardised incidence rate in the historic data for all cancer sites 
combined, the demographic model gives the lowest projected numbers (Figures 2.3, 2.4). Nordpred 
projections are within the HD projection limits for females, but are a little below the lower bounds of 
projection for males, probably because the five-year aggregated data is less affected by small changes in trend 
around the year 2000. The 95% confidence limits for the HD four models overlap for most time periods, and 
these limits are similar for all models. It is important to note that the Nordpred software models each age 
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group separately and that there can be an apparent discrepancy between the aggregate historic trend and a 
projection which is based on the sum of trends for different age groups. This also occurs in the HD models (1 
and 3) where each age group is fitted to a different slope, and can give an apparent discontinuity between the 
historic and modelled numbers. 
Figure 2.3. Projections of cancer cases based on HD models 1-4, Nordpred and demographic trends, using M0F1 population 
projections: all invasive cancers 
females males 
  
Figure 2.4. Projections of cancer cases based on HD models 1-4 (with 95% projection limits), Nordpred and demographic trends, 
using M0F1 population projections: all invasive cancers 
females males 
  
Note. Nordpred produces projections for aggregate five-year periods. Figures 2.3 and 2.4 use linear interpolation and extrapolation to 
project the average midpoint values (2017, 2022, 2027, 2032 and 2037) to the years 2015, 2020, 2050, 2030, 2035 and 2040. 
2.5 Treatments 
For each registered cancer case, the Registry records whether the patient had a specified modality of 
treatment (cancer-directed surgery, chemotherapy or radiotherapy) as part of the initial treatment regime. 
The proportion of patients estimated to have each treatment has been extrapolated to 2025, using the 
projected number of cases and the treatment proportions in 2010. Long-term treatment patterns are difficult 
to project, so we have given data for a more recent period than for the incidence numbers, and with the 
caution that the projections depend on an assumption of stability in treatment practices (i.e. no increase or 
decrease in the use of therapies).  
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All invasive cancer sites combined 10 
Projections by cancer site 
3. All invasive cancer sites combined 
Trends 
Figure 3.1. All invasive cancer sites combined; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-1999 1.4  (0.2, 2.6) 
1999-2010 3.5  (3.2, 3.8) 
1994-1999 1.0  (0.0, 2.0) 
1999-2010 4.2  (3.9, 4.4) 
 
Figure 3.2. All invasive cancer sites combined; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2005 1.2  (0.8, 1.7) 
2005-2010 3.5  (2.1, 4.9) 
1994-1998 -0.2  (-1.4, 1.0) 
1998-2010 1.8  (1.6, 2.0) 
Case numbers increased between 1994 and 2010. Between 1994 and 1999, there was a significant increase of 1.4% annually for 
females and 1.0% for males, with a sharper increase, 3.5% annually for females and 4.2% for males, from 1999 onwards.  
The age-standardised incidence rates also increased during 1994-2010, but the increase was not significant for males before 
1998. In contrast to case numbers, the overall increase in incidence rate was greater for females. 
Projections 
For females, the base of projection for the HD models was 2005-2010, and for males 1998-2010. HD model 4 gave the best fit for 
both males and females. For both sexes the HD projections of the number of cases were above those due to demographic 
change alone (Figure 3.3, Table 3.1). Nordpred gave a higher estimate of female incidence and a slightly lower estimate of male 
incidence than the HD model; these were outside the 95% confidence limits of the HD model. The models project that female 
case numbers will increase by 86%-125% between 2010 and 2040 and male cases by 126%-133%, with proportionate increases 
in treatment rates (Table 3.2). 
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Figure 3.3. Projected numbers of all invasive cancers, based on M1F0 population projections 2015-2040, with actual numbers 
1995-2010 
females males 
 
   
Table 3.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): all invasive cancers 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010 13185     
2015 14322  (9%) 14602  (11%) 14271  (8%) 13975  (6%) 14566  (10%) 
2020 16172  (23%) 17624  (34%) 16155  (23%) 15832  (20%) 16477  (25%) 
2025 18202  (38%) 20647  (57%) 18284  (39%) 17931  (36%) 18637  (41%) 
2030 20295  (54%) 23670  (80%) 20461  (55%) 20077  (52%) 20846  (58%) 
2035 22368  (70%) 26693  (102%) 22580  (71%) 22163  (68%) 22998  (74%) 
2040 24287  (84%) 29715  (125%) 24548  (86%) 24098  (83%) 24998  (90%) 
      
males 
2010 15295     
2015 17008  (11%) 15916  (4%) 18880  (23%) 18539  (21%) 19220  (26%) 
2020 19692  (29%) 19643  (28%) 21640  (41%) 21265  (39%) 22015  (44%) 
2025 22658  (48%) 23370  (53%) 24858  (63%) 24442  (60%) 25274  (65%) 
2030 25775  (69%) 27097  (77%) 28387  (86%) 27923  (83%) 28851  (89%) 
2035 28855  (89%) 30824  (102%) 32026  (109%) 31508  (106%) 32545  (113%) 
2040 31704 (107%) 34551 (126%) 35561 (133%) 34986 (129%) 36137 (136%) 
 
Table 3.2 Number of cancers treated in 2010, with estimates for 2025, all invasive cancers 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 13185 18202 20647 18284 
surgery 9019 12450 14123 12506 
chemotherapy 3429 4734 5370 4755 
radiotherapy 3758 5187 5884 5211 
males     
all cases 15295 22658 23370 24858 
surgery 8382 12417 12807 13622 
chemotherapy 2925 3897 4020 4276 
radiotherapy 4766 5483 5655 6016 
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4. All invasive cancer sites combined, excluding non-melanoma skin cancer 
Non-melanoma skin cancers have been excluded from this analysis, as their recorded incidence is more dependent on case-
finding than most other cancers. 
Trends 
Figure 4.1. All invasive cancer sites combined, excluding non-melanoma skin; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2000 0.4  (-1.5, 2.3) 
2000-2010 4.5  (3.7, 5.3) 
1994-2001 -0.4  (-1.4, 0.6) 
2001-2010 6.0  (5.4, 6.7) 
 
Figure 4.2. All invasive cancer sites combined, excluding non-melanoma skin; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2006 1.5  (1.1, 1.8) 
2006-2010 4.0  (2.2, 5.9) 
1994-2010 1.6  (1.4, 1.8) 
Case numbers increased between 1994 and 2010 (Figure 4.1). This trend was not significant between 1994 and 2000, but from 
2000 onwards the numbers increased by 4.5% annually for females and 6.0% for males. The age-standardised incidence rates 
also increased during 1994-2010, but the increase was significant throughout—1.5% annually from 1994 to 2006 and 4.0% 
thereafter for females, and 1.6% annually from 1994 to 2010 for males (Figure 4.2). 
Projections 
For females, the base of projection for the HD models was 2006-2010, and for males 1994-2010. HD model 2 gave the best fit for 
females and model 4 for males. For females the HD projections of the number of cases were below those due to demographic 
change alone while for males they were very close (Figure 4.3, Table 4.1). Nordpred gave a higher estimate of female incidence 
and a slightly lower estimate of male incidence than the HD model; these were outside the 95% confidence limits of the HD 
model. The models project that female case numbers will increase by 48%-112% between 2010 and 2040; male cases are 
projected to increase by 114%-128% in the same period, with proportionate increases in treatment rates (Table 4.2).  
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Figure 4.3. Projected numbers of all invasive cancers, excluding non-melanoma skin, based on M1F0 population projections 2015-
2040, with actual numbers 1995-2010 
females males 
    
Table 4.1 Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): all invasive cancers, 
excluding non-melanoma skin 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010         9266     
2015 10192  (10%) 10362  (12%) 9768  (5%) 9238  (0%) 10297  (11%) 
2020 11471  (24%) 12225  (32%) 10754  (16%) 9766  (5%) 11743  (27%) 
2025 12849  (39%) 14087  (52%) 11785  (27%) 10233  (10%) 13338  (44%) 
2030 14233  (54%) 15950  (72%) 12702  (37%) 10507  (13%) 14898  (61%) 
2035 15576  (68%) 17813  (92%) 13397  (45%) 10515  (13%) 16279  (76%) 
2040 16787  (81%) 19676  (112%) 13676  (48%) 10184  (10%) 17168  (85%) 
      
males 
2010        10436     
2015 11816  (13%) 10971  (5%) 12757  (22%) 12477  (20%) 13037  (25%) 
2020 13635  (31%) 13252  (27%) 14605  (40%) 14297  (37%) 14914  (43%) 
2025 15639  (50%) 15534  (49%) 16753  (61%) 16411  (57%) 17095  (64%) 
2030 17734  (70%) 17815  (71%) 19097  (83%) 18716  (79%) 19478  (87%) 
2035 19784  (90%) 20097  (93%) 21500  (106%) 21075  (102%) 21926  (110%) 
2040 21655 (108%) 22378 (114%) 23822 (128%) 23351 (124%) 24293 (133%) 
 
Table 4.2 Number of cancers treated in 2010, with estimates for 2025, all invasive cancers excluding non-melanoma skin 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 9266 12849 14087 11785 
surgery 5680 7876 8636 7224 
chemotherapy 3428 4754 5212 4361 
radiotherapy 3669 5088 5579 4667 
males     
all cases 10436 15639 15534 16753 
surgery 4154 6224 6182 6668 
chemotherapy 2962 3920 3893 4199 
radiotherapy 4622 5301 5266 5679 
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5. Cancer of the head and neck  
Cancer of the head and neck includes a number of distinct sub-sites, of which larynx is by far the commonest (Table 5.1). 
Table 5.1. Subsites of cancer of the head and neck; number of cases and % of all cancers of the head and neck 2006-2010 
site ICD10 code 
average cases 
2006-2010 
% of cases 
2006-2010 
site ICD10 code 
average cases 
2006-2009 
% of cases 
2006-2010 
base of tongue C01 26 5.1% tonsil C09 41 8.1% 
other tongue C02 59 11.9% oropharynx C10 10 1.9% 
gum C03 15 3.0% nasopharynx C11 16 3.2% 
floor of mouth C04 25 5.0% pyriform C12 24 4.7% 
palate C05 19 3.8% hypopharynx C13 15 3.0% 
other mouth C06 28 5.5% other mouth/pharynx C14 15 2.9% 
parotid C07 30 6.0% nasal cavity/middle ear C30 13 2.7% 
other salivary C08 7 1.4% sinuses C31 10 2.1% 
    larynx C32 148 29.7% 
Trends 
Figure 5.1. Cancer of the head and neck; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2001 1.6 (-1.8, 5.0) 
2001-2010 7.9 (5.9, 9.9) 
1994-2001 -1.0 (-3.0, 1.0) 
2001-2010 5.2 (3.9, 6.5) 
 
Figure 5.2. Cancer of the head and neck; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 3.7 (2.7, 4.7) 1994-2010 0.3 (-0.6, 1.3) 
Case numbers increased for females by 1.6% annually between 1994 and 2001 and by 7.9% annually from 2001 onward. For 
males there was no significant trend in numbers until 2001 and a 5.2% increase thereafter (Figure 5.1). Age-standardised 
incidence rates for females increased by 3.7% annually between 1994 and 2010, but there was no significant change for males 
(Figure 5.2). 
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Projections 
For both sexes the base of projection for the HD model was 1994-2010. HD model 4 gave the best fit for females, and model 3 
for males. For both sexes the HD estimates were close to those due to demographic change alone (Figure 5.3, Table 5.1). The 
Nordpred estimates were much higher than the HD estimates for females, and a little higher for males; the latter was mostly 
within the HD model 95% confidence limits. The models project that female case numbers will increase by 46%-128% between 
2010 and 2040 and male cases by 66%-108%, with proportionate increases in treatment rates (Table 5.2). 
Figure 5.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the head and neck 
females males 
   
Table 5.1.Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the head and 
neck 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        178     
2015 139  (-22%) 165  (-7%) 157  (-12%) 132  (-26%) 183  (3%) 
2020 183  (3%) 214  (20%) 177  (-1%) 149  (-16%) 204  (15%) 
2025 204  (15%) 262  (47%) 198  (11%) 169  (-5%) 227  (27%) 
2030 225  (26%) 310  (74%) 220  (23%) 189  (6%) 250  (41%) 
2035 245  (38%) 358  (101%) 241  (35%) 208  (17%) 273  (54%) 
2040 264  (48%) 406  (128%) 259  (46%) 225  (26%) 293  (65%) 
males      
 
2010        412     
2015 436  (6%) 462  (12%) 448  (9%) 399  (-3%) 497  (21%) 
2020 494  (20%) 542  (31%) 498  (21%) 438  (6%) 557  (35%) 
2025 555  (35%) 621  (51%) 551  (34%) 478  (16%) 624  (51%) 
2030 615  (49%) 700  (70%) 603  (46%) 514  (25%) 693  (68%) 
2035 668  (62%) 779  (89%) 649  (58%) 541  (31%) 757  (84%) 
2040 708  (72%) 858  (108%) 684  (66%) 556  (35%) 812  (97%) 
 
Table 5.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the head and neck 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 178 204 262 198 
surgery 133 153 196 148 
chemotherapy 22 25 32 25 
radiotherapy 93 106 137 103 
males     
all cases 412 555 621 552 
surgery 218 293 328 291 
chemotherapy 121 154 173 153 
radiotherapy 332 372 417 370 
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6. Cancer of the oesophagus 
Cancer of the oesophagus is of two main types: squamous carcinoma and adenocarcinoma. Squamous carcinomas have 
remained fairly constant in number since 1994, but adenocarcinomas are increasing rapidly, by 4% a year for females and 5% for 
males [23]. Due to the small number of cases, it was not feasible to model these histological types separately, and projections 
are presented here for all oesophageal cancers combined. 
Trends 
Figure 6.2. Cancer of the oesophagus; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.6 (-0.1, 1.3) 1994-2010 2.6 (1.7, -1.0) 
 
Figure 6.3. Cancer of the oesophagus; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 -1.0 (-1.8, -0.2) 1994-2010 0.3 (-0.6, 1.2) 
Case numbers did not increase significantly for females from 1994 to 2010, but increased by 2.6% annually for males (Figure 
6.2). Age-standardised incidence fell significantly for females, by 1.0% a year, and remained constant for males (Figure 6.3). 
Projections 
The base of projection for the HD models for both sexes was 1994-2010. HD model 3 gave the best fit for females and model 4 
for males. For females the HD estimates were below those due to demographic change alone (Figure 6.4, Table 6.1). Nordpred 
estimates were close to those of the HD model, but suggest a greater increase in female cases in later years. The models project 
that female case numbers will increase by 84%-123% between 2010 and 2040 and male cases by 112%-160%, with 
proportionate increases in treatment rates (Table 6.2). 
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Figure 6.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the oesophagus 
females males 
  
 
Table 6.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the 
oesophagus 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        127     
2015 154  (21%) 134  (6%) 154  (21%) 125  (-1%) 182  (44%) 
2020 177  (39%) 164  (29%) 167  (32%) 134  (5%) 201  (58%) 
2025 205  (61%) 194  (53%) 183  (44%) 143  (13%) 224  (76%) 
2030 237  (86%) 224  (76%) 201  (58%) 152  (20%) 250  (97%) 
2035 271  (113%) 254  (100%) 218  (72%) 159  (25%) 278  (119%) 
2040 305  (140%) 283  (123%) 233  (84%) 163  (28%) 303  (139%) 
males 
2010        243     
2015 296  (22%) 263  (8%) 342  (41%) 303  (25%) 380  (56%) 
2020 342  (41%) 313  (29%) 390  (61%) 349  (44%) 431  (78%) 
2025 393  (62%) 364  (50%) 446  (84%) 402  (65%) 491  (102%) 
2030 449  (85%) 415  (71%) 509  (109%) 460  (89%) 557  (129%) 
2035 501  (106%) 465  (91%) 571  (135%) 519  (114%) 623  (156%) 
2040 549  (126%) 516  (112%) 631  (160%) 576  (137%) 687  (183%) 
      
Table 6.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the oesophagus 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 127 205 194 183 
surgery 29 47 44 42 
chemotherapy 50 81 76 72 
radiotherapy 53 85 81 76 
males     
all cases 243 393 364 446 
surgery 90 145 135 165 
chemotherapy 125 167 154 189 
radiotherapy 153 176 163 200 
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7. Cancer of the stomach 
Trends 
Figure 7.1. Cancer of the stomach; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.0  (-0.7, 0.7) 
1994-2003 -1.5  (-2.3, -0.7) 
2003-2010 3.5  ( 2.3,  4.7) 
 
Figure 7.2. Cancer of the stomach; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 -1.6 (-2.3, -1.0) 
1994-2003 -3.2 (-4.0, -2.3) 
2003-2010 0.8 (-0.5, 2.2) 
Case numbers did not change significantly for females from 1994 to 2010. They fell by 1.5% annually between 1994 and 2003 
but increased for males by 3.5% annually from 2003 onward (Figure 7.1). Age-standardised incidence rates fell by 1.6% a year for 
females. For males there was a significant decrease of 3.2% annually from 1994 to 2003, with no significant trend after that time 
(Figure 7.2). 
Projections 
The base of projection for the HD model for females was 1994-2010 and for males 2003-2010. HD model 3 gave the best fit for 
both males and females. For both sexes the HD projections of the number of cases were well below those due to demographic 
change alone (Figure 7.3, Table 7.1). The Nordpred projections were similar to those of the HD model. The models project that 
female case numbers will increase by 32%-74% between 2010 and 2040, and male cases by 27%-59%, with proportionate 
increases in treatment rates (Table 7.2). 
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Figure 7.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the stomach 
females males 
  
 
Table 7.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the stomach 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        178     
2015 221  (24%) 196  (10%) 197  (11%) 165  (-7%) 229  (29%) 
2020 253  (42%) 219  (23%) 205  (15%) 169  (-5%) 241  (35%) 
2025 291  (63%) 242  (36%) 214  (20%) 173  (-3%) 256  (44%) 
2030 333  (87%) 264  (49%) 224  (26%) 176  (-1%) 272  (53%) 
2035 378  (112%) 287  (61%) 231  (30%) 177  (-1%) 286  (61%) 
2040 423  (138%) 310  (74%) 236  (32%) 174  (-2%) 297  (67%) 
males 
2010         364     
2015 399  (9%) 339  (-7%) 393  (8%) 347  (-5%) 439  (21%) 
2020 467  (28%) 387  (6%) 410  (13%) 357  (-2%) 462  (27%) 
2025 542  (49%) 435  (19%) 428  (18%) 367  (1%) 489  (34%) 
2030 621  (71%) 483  (33%) 445  (22%) 375  (3%) 516  (42%) 
2035 699  (92%) 531  (46%) 457  (26%) 376  (3%) 539  (48%) 
2040 773  (112%) 579  (59%) 463  (27%) 371  (2%) 554  (52%) 
 
Table 7.2. Number of cancers treated in 2010, with estimates for 2025: cancer of the stomach 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 178 291 242 214 
surgery 70 114 94 84 
chemotherapy 52 85 70 62 
radiotherapy 18 29 24 22 
males     
all cases 364 542 435 428 
surgery 172 256 206 203 
chemotherapy 163 221 177 175 
radiotherapy 80 93 74 73 
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8. Cancer of the colon 
Trends 
Figure 8.1. Cancer of the colon; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-1998 -0.8 (-3.9, 2.3) 
1998-2010 2.4 (1.9, 3.0) 
1994-2002 1.0 (-0.4, 2.4) 
2002-2010 4.4 (3.1, 5.7) 
 
Figure 8.2. Cancer of the colon; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.1 (-0.4, 0.5) 1994-2010 0.6 (0.1, 1.2) 
Case numbers did not change significantly for females from 1994 to 1998. Between 1998 and 2010 they increased significantly, 
by 2.4% annually. For males there was no significant trend from 1994 to 2002 and a significant increase, 4.4% annually, 
thereafter (Figure 8.1). Age-standardised incidence rates did not change significantly for females, and rose slightly, by 0.6% a 
year, for males during 1994-2010 (Figure 8.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for both males and 
females. For females the HD estimates were the same as for the Nordpred and demographic models (Figure 8.3, Table 8.1) while 
for males the demographic projections were intermediate between those from Nordpred and the HD model. The models project 
that female case numbers will increase by 116%-117% between 2010 and 2040, and male cases by 104%-156%, with 
proportionate increases in treatment rates (Table 8.2).  
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Figure 8.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the colon 
females males 
  
 
Table 8.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the colon 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010          703     
2015   818  (16%)   802  (14%)   811  (15%)   753  (7%)   870  (24%) 
2020   937  (33%)   947  (35%)   928  (32%)   865  (23%)   991  (41%) 
2025 1075  (53%) 1092  (55%) 1066  (52%)   997  (42%) 1134  (61%) 
2030 1226  (74%) 1237  (76%) 1216  (73%) 1141  (62%) 1291  (84%) 
2035 1382  (97%) 1382  (97%) 1370  (95%) 1289  (83%) 1451  (106%) 
2040 1529  (118%) 1526  (117%) 1518  (116%) 1431  (103%) 1605  (128%) 
males 
2010           872     
2015 1033  (19%) 974  (12%) 1158  (33%) 1087  (25%) 1228  (41%) 
2020 1210  (39%) 1136  (30%) 1331  (53%) 1255  (44%) 1407  (61%) 
2025 1409  (62%) 1297  (49%) 1537  (76%) 1455  (67%) 1620  (86%) 
2030 1620  (86%) 1458  (67%) 1764  (102%) 1675  (92%) 1854  (113%) 
2035 1829  (110%) 1620  (86%) 1998  (129%) 1901  (118%) 2096  (140%) 
2040 2030  (133%) 1781  (104%) 2230  (156%) 2125  (144%) 2334  (168%) 
 
Table 8.2. Number of cancers treated in 2010, with estimates for 2025: cancer of the colon 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 703 1075 1092 1066 
surgery 557 853 866 845 
chemotherapy 257 393 399 389 
radiotherapy 38 58 59 58 
males     
all cases 872 1409 1297 1537 
surgery 700 1132 1041 1235 
chemotherapy 381 520 479 567 
radiotherapy 56 65 60 71 
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9. Cancer of the rectum and anus 
Trends 
Cancers of the rectum and anus consist of three subsites: rectosigmoid junction, rectum and anus. Rectal cancers make up the 
majority and anal cancers are uncommon (Table 9.1). 
Table 9.1. Subsites of cancers of the rectum and anus; number of cases and % of all cancers of the rectum and anus 2006-2010 
  females males 
site ICD10 code average number of cases % of cases average number of cases % of cases 
rectosigmoid junction C19 55 23% 86 20% 
rectum C20 168 69% 325 77% 
anus C21 19 8% 13 3% 
 
Figure 9.1. Cancer of the rectum and anus; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 2.2 (1.5, 2.9) 1994-2010 2.2 (1.7, 2.7) 
 
Figure 9.2. Cancer of the rectum and anus; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.4 (-0.4, 1.2) 1994-2010 0.0 (-0.6, 0.6) 
Case numbers increased significantly for females and males from 1994 to 1998, by 2.2% a year (Figure 9.1). There was no 
significant trend for either sex in age-standardised incidence rates (Figure 9.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 3 gave the best fit for both males and 
females. For both sexes the HD projections of the number of cases were almost identical to those due to demographic change 
alone (Figure 9.3, Table 9.2). The Nordpred projections were within the 95% confidence limits of the HD model for females, but 
below them for males. The model projects that female case numbers will increase by 83%-110% between 2010 and 2040 and 
male cases by 77%-105%, with proportionate increases in treatment rates (Table 9.2). 
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Figure 9.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the rectum and anus 
females males 
  
 
Table 9.2.Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the rectum 
and anus 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010         338     
2015 367  (9%) 343  (2%) 367  (9%) 323  (-4%) 411  (22%) 
2020 417  (23%) 417  (23%) 413  (22%) 360  (7%) 466  (38%) 
2025 475  (40%) 490  (45%) 465  (38%) 399  (18%) 531  (57%) 
2030 535  (58%) 564  (67%) 519  (54%) 437  (29%) 601  (78%) 
2035 594  (76%) 637  (89%) 572  (69%) 470  (39%) 673  (99%) 
2040 648  (92%) 711  (110%) 620  (83%) 497  (47%) 742  (120%) 
males 
2010           558     
2015   653  (17%) 567  (2%)   714  (28%) 651  (17%)   776  (39%) 
2020   755  (35%) 651  (17%)   794  (42%) 719  (29%)   870  (56%) 
2025   868  (56%) 734  (32%)   886  (59%) 792  (42%)   979  (75%) 
2030   984  (76%) 818  (47%)   981  (76%) 865  (55%) 1098  (97%) 
2035 1094   (96%) 901  (62%) 1069  (92%) 926  (66%) 1212  (117%) 
2040 1194  (114%) 985  (77%) 1146  (105%) 975  (75%) 1317  (136%) 
 
Table 9.2. Number of cancers treated in 2010, with estimates for 2025: cancer of the rectum and anus 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 338 475 490 465 
surgery 243 341 352 334 
chemotherapy 165 232 240 227 
radiotherapy 173 243 251 238 
males     
all cases 558 868 734 886 
surgery 416 647 548 661 
chemotherapy 370 492 416 502 
radiotherapy 391 449 380 459 
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10.  Cancer of the liver, biliary tract and gallbladder 
Trends 
Cancer of the liver, biliary tract and gallbladder (hepatobiliary) cancers consist of hepatocellular carcinoma of the liver, 
intrahepatic bile duct carcinoma, extrahepatic bile duct carcinoma and a small number of other histological types. 37% were not 
histologically verified (Table 10.1).  
Table 10.1. Subsites of cancers of liver, biliary tract and gallbladder; number of cases and % of all cancers of the liver, biliary tract 
and gallbladder 2006-2010 
  adenocarcinoma hepatocellular carcinoma other and unspecified types 
site ICD10 code average number of cases % of cases average number of cases % of cases average number of cases % of cases 
liver C22 30 12% 53 21% 59 23% 
gallbladder C23 26 11% <1 0% 14 6% 
other biliary C24 47 19% 1 0% 20 8% 
Total  103 41% 54 22% 93 37% 
 
Figure 10.2 Cancer of the liver, biliary tract and gallbladder; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 4.2 (2.9, 5.7) 1994-2010 6.0 (4.6, 7.3) 
 
Figure 10.3 Cancer of the liver, biliary tract and gallbladder; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 6.1 (3.9, 8.4) 1994-2010 6.7 (5.2, 8.2) 
Case numbers increased significantly for females and males from 1994 to 2010, by 4.2% annually for females and 6.0% for males 
(Figure 10.1). There was also a significant increase in age-standardised incidence rates, 6.1% annually for females and 6.7% for 
males (Figure 10.2). Most of this increase was in adenocarcinoma [24]. 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for both sexes (Figure 
10.3). The three sets of projections were close for females, but Nordpred projected a higher incidence for males from 2020 
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onwards than the other methods. The models project that female case numbers will increase by 127%-148% between 2010 and 
2040 and male cases by 113%-155% (Table 10.2), with proportionate increases in treatment rates (Table 10.3). 
Figure 10.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the liver, biliary tract and gallbladder  
females males 
  
 
Table 10.2. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the liver, 
biliary tract and gallbladder  
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        131     
2015 161  (23%) 163  (25%) 157  (20%) 132  (0%) 183  (39%) 
2020 185  (41%) 196  (49%) 179  (37%) 152  (16%) 206  (57%) 
2025 213  (63%) 228  (74%) 205  (57%) 176  (34%) 235  (79%) 
2030 246  (88%) 260  (99%) 235  (80%) 204  (55%) 267  (104%) 
2035 281  (115%) 293  (123%) 267  (104%) 233  (78%) 301  (130%) 
2040 315  (141%) 325  (148%) 298  (127%) 262  (100%) 334  (155%) 
males 
2010        199     
2015 221  (11%) 215  (8%) 224  (13%) 193  (-3%) 255  (28%) 
2020 257  (29%) 274  (38%) 256  (29%) 223  (12%) 290  (46%) 
2025 298  (50%) 332  (67%) 295  (48%) 258  (30%) 331  (66%) 
2030 340  (71%) 391  (96%) 336  (69%) 297  (49%) 376  (89%) 
2035 382  (92%) 449  (126%) 380  (91%) 337  (70%) 423  (113%) 
2040 421  (111%) 507  (155%) 423  (113%) 377  (90%) 469  (136%) 
 
Table 10.3. Number of cancers treated in 2010, with estimates for 2025: cancer of the liver, biliary tract and gallbladder  
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 131 213 228 205 
surgery 33 54 58 53 
chemotherapy 34 56 60 54 
radiotherapy 5 8 9 8 
males     
all cases 199 298 332 295 
surgery 54 80 90 80 
chemotherapy 73 98 110 97 
radiotherapy 17 19 22 19 
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11. Cancer of the pancreas 
Trends 
Figure 11.1. Cancer of the pancreas; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 2.3 (1.4, 3.2) 1994-2010 3.0 (2.0, 3.9) 
 
Figure 11.2. Cancer of the pancreas; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.6 (-0.3, 1.6) 1994-2010 0.9 (0.0, 1.9) 
Case numbers of cancer of the pancreas increased significantly for females and males from 1994 to 2010, by 2.3% annually for 
females and 3.0% for males (Figure 11.1). There was a slight upward trend in age-standardised incidence rates for both sexes but 
this was not statistically significant (Figure 11.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for both males and 
females. The HD projections of the number of cases were close to those due to demographic change alone (Figure 11.3, Table 
11.1). The Nordpred and demographic projections for both sexes were mostly within the 95% confidence limits for the HD 
models. The models project that female case numbers will increase by 140%-172% between 2010 and 2040 and male cases by 
129%-152%, with proportionate increases in treatment rates (Table 11.2).  
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Figure 11.3.Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the pancreas 
females males 
  
 
Table 11.1.Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the pancreas 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        205     
2015 275  (34%) 263  (28%) 260  (27%) 224  (9%) 296  (44%) 
2020 316  (54%) 322  (57%) 296  (44%) 253  (23%) 340  (66%) 
2025 366  (79%) 381  (86%) 340  (66%) 286  (40%) 394  (92%) 
2030 423  (106%) 440  (114%) 390  (90%) 322  (57%) 458  (123%) 
2035 482  (135%) 498  (143%) 442  (115%) 356  (74%) 527  (157%) 
2040 540  (164%) 557  (172%) 492  (140%) 386  (88%) 598  (192%) 
males 
2010        258     
2015 299  (16%) 269  (4%) 338  (31%) 299  (16%) 376  (46%) 
2020 349  (35%) 333  (29%) 387  (50%) 346  (34%) 428  (66%) 
2025 404  (57%) 397  (54%) 446  (73%) 401  (56%) 491  (90%) 
2030 463  (79%) 461  (79%) 511  (98%) 462  (79%) 559  (117%) 
2035 524  (103%) 525  (104%) 581  (125%) 528  (105%) 633  (146%) 
2040 580  (125%) 590  (129%) 650  (152%) 593  (130%) 706  (174%) 
 
Table 11.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the pancreas 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 205 366 381 340 
surgery 33 59 62 55 
chemotherapy 53 94 98 87 
radiotherapy 15 26 27 24 
males     
all cases 258 404 397 446 
surgery 52 81 80 90 
chemotherapy 123 167 164 184 
radiotherapy 46 53 52 58 
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12. Cancer of the lung 
Trends 
Figure 12.1. Cancer of the lung; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 3.9 (3.6, 4.2) 
1994-2005 0.7 (0.1, 1.4) 
2005-2010 3.3 (1.3, 5.3) 
 
Figure 12.2. Cancer of the lung; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 2.3 (2.0, 2.7) 1994-2010 -0.7 (-1.0, -0.3) 
Lung cancer case numbers increased significantly for females from 1994 to 2010, by 3.9% annually. For males the numbers 
increased by 0.7% annually from 1994 to 2005 and by 3.3% thereafter (Figure 12.1). The incidence rates increased by 2.3% 
annually in females and decreased by 0.7% annually in males (Figure 12.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. Two HD models—1 and 4—gave an equally good fit for 
females, while HD model 4 gave the best fit for males. As the projected number of cases from the two HD models for females is 
quite different, they are both shown below (Figure 12.3). The Nordpred projections lie between the two HD projections. For 
males the HD projections were a little above those produced by Nordpred and both were below the demographic projections 
(Figure 12.3, Table 12.1). The models project that female case numbers will increase by 77%-196% between 2010 and 2040 and 
male cases by 52%-72%, with proportionate increases in treatment rates (Table 12.2). 
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Figure 12.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the lung 
females (HD model 1) males 
  
females (HD model 4)  
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Table 12.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the lung 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females  (HD model 1) 
2010          957     
2015 1013  (6%) 1068  (12%) 1108  (16%) 1033  (8%) 1183  (24%) 
2020 1161  (21%) 1307  (37%) 1366  (43%) 1274  (33%) 1459  (52%) 
2025 1334  (39%) 1545  (61%) 1682  (76%) 1565  (64%) 1798  (88%) 
2030 1515  (58%) 1784  (86%) 2042  (113%) 1896  (98%) 2188  (129%) 
2035 1694  (77%) 2022  (111%) 2429  (154%) 2247  (135%) 2611  (173%) 
2040 1862  (95%) 2260  (136%) 2830  (196%) 2606  (172%) 3054  (219%) 
females (HD model 4) 
2010          957     
2015 1013  (6%) 1068  (12%) 916  (-4%)   853  (-11%)   979  (2%) 
2020 1161  (21%) 1307  (37%) 1053  (10%)   985  (3%) 1121  (17%) 
2025 1334  (39%) 1545  (61%) 1210  (26%) 1136  (19%) 1283  (34%) 
2030 1515  (58%) 1784  (86%) 1374  (44%) 1295  (35%) 1453  (52%) 
2035 1694  (77%) 2022  (111%) 1538  (61%) 1453  (52%) 1623  (70%) 
2040 1862  (95%) 2260  (136%) 1693  (77%) 1603  (68%) 1783  (86%) 
males 
2010        1307     
2015 1477  (13%) 1232  (-6%) 1538  (18%) 1438  (10%) 1638  (25%) 
2020 1728  (32%) 1383  (6%) 1677  (28%) 1553  (19%) 1801  (38%) 
2025 2012  (54%) 1534  (17%) 1834  (40%) 1678  (28%) 1990  (52%) 
2030 2314  (77%) 1685  (29%) 1992  (52%) 1797  (37%) 2186  (67%) 
2035 2610  (100%) 1836  (40%) 2132  (63%) 1894  (45%) 2370  (81%) 
2040 2889  (121%) 1987  (52%) 2245  (72%) 1962  (50%) 2527  (93%) 
 
Table 12.2. Number of cancers treated in 2010, with estimates for 2025, cancer of the lung  
 2010 2025 demography 2025 Nordpred 2025 HD model 1 2025 HD model 4 
females      
all cases 957 1334 1545 1682 1210 
surgery 189 263 304 331 238 
chemotherapy 320 446 516 562 404 
radiotherapy 409 570 660 718 517 
males      
all cases  1307 2012 1534  1834 
surgery 248 382 291  348 
chemotherapy 477 650 495  592 
radiotherapy 745 867 661  790 
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13. Melanoma of the skin 
Trends 
Figure 13.1. Melanoma of the skin; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-1998 -0.4 (-5.2, 4.7) 
1998-2002 8.8 (1.0, 17.2) 
2002-2006 1.9 (-4.4, 8.8) 
2006-2010 9.2 (5.2, 13.3) 
1994-2010 7.4 (6.5, 8.3) 
 
Figure 13.2. Melanoma of the skin; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 2.8 (2.0, 3.6) 1994-2010 5.1 (4.1, 6.0) 
The rate of increase in female melanoma numbers varied over the period 1994 to 2010, with a rapid increase (9.2% annually) 
between 2006 and 2010. For males there was a similar but more constant trend, 7.4% annually between 1994 and 2010 (Figure 
13.1). For both males and females there was also an upward trend in age-standardised incidence rates, 2.8% annually for 
females and 5.1% for males (Figure 13.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 1 gave the best fit for females and males. For 
both females and males the projected number of cases from the HD models was well above that projected by demographic 
change or the Nordpred model (Figure 13.3, Table 13.1).  The models project that female case numbers will increase by a factor 
of 93%-175% between 2010 and 2040 and male cases by 134%-327%, with proportionate increases in treatment rates (Table 
13.2).  
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Figure 13.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: melanoma of the skin 
females males 
  
 
Table 13.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): melanoma of the skin 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010         536     
2015 500  (-7%)   564  (5%)   620  (16%)   562  (5%)   677  (26%) 
2020 554  (3%)   658  (23%)   757  (41%)   687  (28%)   826  (54%) 
2025 607  (13%)   752  (40%)   911  (70%)   826  (54%)   997  (86%) 
2030 659  (23%)   846  (58%) 1081  (102%)   978  (82%) 1185  (121%) 
2035 713  (33%)   940  (75%) 1269  (137%) 1143  (113%) 1395  (160%) 
2040 766  (43%) 1034  (93%) 1476  (175%) 1325  (147%) 1628  (204%) 
males 
2010         385     
2015 398  (3%) 441  (15%)   564  (46%)   507  (32%)   620  (61%) 
2020 452  (17%) 533  (38%)   724  (88%)   653  (70%)   795  (107%) 
2025 508  (32%) 625  (62%)   914  (138%)   824  (114%) 1004  (161%) 
2030 565  (47%) 716  (86%) 1137  (195%) 1022  (166%) 1251  (225%) 
2035 622  (62%) 808  (110%) 1381  (259%) 1235  (221%) 1527  (297%) 
2040 674  (75%) 900  (134%) 1645  (327%) 1461  (279%) 1829  (375%) 
 
Table 13.2 Number of cancers treated in 2010, with estimates for 2025: melanoma of the skin 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 536 607 752 911 
surgery 514 582 721 874 
chemotherapy 26 29 36 44 
radiotherapy 20 22 28 34 
males     
all cases 385 508 625 914 
surgery 357 471 579 848 
chemotherapy 27 34 42 61 
radiotherapy 36 41 50 73 
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14. Non-melanoma cancer of skin  
Trends 
Figure 14.1. Non-melanoma skin cancer; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2000 0.4 (-1.5, 2.3) 
2000-2010 4.5 (3.7, 5.3) 
1994-2001 -0.4 (-1.4, 0.6) 
2001-2010 6.0 (5.4, 6.7) 
 
Figure 14.2. Non-melanoma skin cancer; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2001 -0.5 (-1.9, 1.0) 
2001-2010 2.7 (1.7, 3.7) 
1994-2001 -1.9 (-2.8, -1.0) 
2001-2010 3.4 (2.8, 4.1) 
There was no significant trend in case numbers for females between 1994 and 2000, followed by a 4.5% annual increase from 
2000 to 2010. For males there was a similar trend, with the increase in case numbers (6.0% annually) beginning in 2001 (Figure 
14.1). Trends in age-standardised incidence rates followed the same patterns with a significant 2.7% annual increase for females 
and 3.4% for males from 2001 to 2010 (Figure 14.2). 
Projections 
The base of projection for the HD model for both sexes was 2001-2010. HD model 1 gave the best fit for both females and 
males. For both females and males the HD estimates were well above those due to demographic change alone and for males 
also much higher than the Nordpred projections (Figure 14.3, Table 14.1). The model projects that female case numbers will 
increase by 162%-235% between 2010 and 2040 and male cases by 157%-356%, with proportionate increases in treatment rates 
(Table 14.2). 
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Figure 14.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: non-melanoma skin cancer 
females males 
  
 
Table 14.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): non-melanoma skin 
cancer 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010          3919     
2015   4131 (5%)   4275 (9%)   4848 (24%)   4633 (18%)   5063 (29%) 
2020   4701 (20%)   5474 (40%)   6069 (55%)   5739 (46%)   6400 (63%) 
2025   5353 (37%)   6673 (70%)   7565 (93%)   7077 (81%)   8053 (105%) 
2030   6062 (55%)   7872 (101%)   9274 (137%)   8585 (119%)   9963 (154%) 
2035   6791 (73%)   9070 (131%) 11143 (184%) 10205 (160%) 12080 (208%) 
2040   7500 (91%) 10269 (162%) 13138 (235%) 11906 (204%) 14369 (267%) 
males 
2010          4859     
2015   5192 (7%)   5011 (3%)   7273 (50%)   7006 (44%)   7540 (55%) 
2020   6057 (25%)   6502 (34%)   9331 (92%)   8913 (83%)   9749 (101%) 
2025   7020 (44%)   7993 (64%) 11886 (145%) 11258 (132%) 12514 (158%) 
2030   8041 (65%)   9483 (95%) 14943 (208%) 14032 (189%) 15853 (226%) 
2035   9071 (87%) 10974 (126%) 18407 (279%) 17126 (252%) 19689 (305%) 
2040 10049 (107%) 12465 (157%) 22140 (356%) 20410 (320%) 23870 (391%) 
 
Table 14.2. Number of cancers treated in 2010, with estimates for 2025: non-melanoma skin cancer 
 2010 2025 demography 2025 Nordpred 2025 HD model 
females     
all cases 3919 5353 6673 7565 
surgery 3339 4561 5685 6446 
chemotherapy 4 5 7 8 
radiotherapy 94 128 160 182 
males     
all cases 4859 7020 7993 11886 
surgery 4237 6121 6970 10364 
chemotherapy 10 14 16 24 
radiotherapy 206 239 272 404 
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15. Female breast cancer 
Trends 
Figure 15.1. Female breast cancer; case numbers, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 4.0 (3.6, 4.4) 
 
Figure 15.2. Female breast cancer; age-standardised incidence rate, 
1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 1.8 (1.4, 2.3) 
There was a significant upward trend in breast cancer numbers for females between 1994 and 2010 of 4.0% annually. Some 
deviation from this trend can be seen at the time of commencement of BreastCheck in 2001, and at the time of its extension to 
the south and west of the country in 2007 (Figure 15.1) but this seems to be overlaid on a steady long-term upward trend. A 
similar pattern, but with a smaller rate of increase (1.8% annually) can be seen for age-standardised incidence rates (Figure 
15.2). 
Projections 
The base of projection for the HD model was 1994-2010. Two HD models—1 and 4—gave an equally good fit, but give quite 
different estimates, so both are presented here (Figure 15.3, Table 15.1). HD model 1 projects an increase of 152% in cases 
between 2010 and 2040, while HD model 4 projects an increase of 55%. The Nordpred projection (an increase of 113%) lies 
between the two HD projections, with proportionate increases in treatment rates (Table 15.2). 
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Figure 15.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the female breast 
HD model 1 HD model 4 
  
 
Table 15.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the female 
breast 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
 
HD model 1 
2010        2891     
2015 3209  (11%) 3494  (21%) 3631  (26%) 3478  (20%) 3784  (31%) 
2020 3577  (24%) 4024  (39%) 4333  (50%) 4138  (43%) 4527  (57%) 
2025 3937  (36%) 4555  (58%) 5117  (77%) 4870  (68%) 5364  (86%) 
2030 4252  (47%) 5085  (76%) 5894  (104%) 5585  (93%) 6203  (115%) 
2035 4514  (56%) 5615  (94%) 6639  (130%) 6260  (117%) 7018  (143%) 
2040 4701  (63%) 6146  (113%) 7291  (152%) 6835  (136%) 7746  (168%) 
HD model 4 
2010        2891     
2015 3209  (11%) 3494  (21%) 3044  (5%) 2920  (1%) 3167  (10%) 
2020 3577  (24%) 4024  (39%) 3383  (17%) 3251  (12%) 3515  (22%) 
2025 3937  (36%) 4555  (58%) 3735  (29%) 3594  (24%) 3875  (34%) 
2030 4252  (47%) 5085  (76%) 4042  (40%) 3894  (35%) 4190  (45%) 
2035 4514  (56%) 5615  (94%) 4289  (48%) 4134  (43%) 4443  (54%) 
2040 4701  (63%) 6146  (113%) 4472  (55%) 4311  (49%) 4632  (60%) 
 
Table 15.2. Number of cancers treated in 2010, with estimates for 2025, cancer of the female breast 
 2010 2025 demography  2025 Nordpred 2025 HD model 
HD model 1      
all cases 2891 3937 4555 5117 
surgery 2541 3461 4003 4498 
chemotherapy 1388 1890 2186 2456 
radiotherapy 2058 2803 3243 3643 
HD model 4     
all cases 2891 3937 4555 3735 
surgery 2541 3461 4003 3283 
chemotherapy 1388 1890 2186 1793 
radiotherapy 2058 2803 3243 2659 
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16. Cancer of the cervix uteri 
Trends 
Figure 16.1. Cancer of the cervix uteri; case numbers, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 4.5 (3.2, 5.9) 
 
Figure 16.2 Cancer of the cervix uteri; age-standardised incidence 
rate, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 1.9 (0.7, 3.2) 
There was a significant upward trend in cases of cancer of the cervix uteri, of 4.5% annually between 1994 and 2010. Although 
there is some year-to-year variation, this trend seems steady, with no apparent impact of the introduction of the population-
based screening programme, CervicalCheck, in 2008 (Figure 16.1). There was a similar pattern for age-standardised incidence 
rates, with an increase of 1.9% annually (Figure 16.2) although a model with no significant trend before 2006 and an annual 
percentage increase of 3.5% (95% confidence limits 1.4, 5.7) from 2006 to 2010 fitted the data equally well as the linear trend 
shown here (p=0.05). The more conservative long-term trend was chosen, as the recent increase is likely to be partly due to the 
initiation of national cervical screening. 
Projections 
The base of projection for the HD model was 1994-2010. HD model 1 gave the best fit. The HD estimates were well above those 
due to demographic change alone (Figure 16.3, Table 16.1). The Nordpred projections were close to those of the HD model and 
both project that case numbers will increase by 77%-88% between 2015 and 2040, with proportionate increases in treatment 
rates (Table 16.2). 
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Figure 16.3 Projected numbers of incident cases, based on M1F0 
population projections 2015-2040, with actual numbers 1995-2010: 
cancer of the cervix uteri 
 
 
 
Table 16.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the cervix 
uteri 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
 
2010        321     
2015 327  (2%) 361  (13%) 399  (24%) 350  (9%) 448  (40%) 
2020 350  (9%) 410  (28%) 441  (38%) 383  (19%) 500  (56%) 
2025 361  (13%) 459  (43%) 480  (49%) 410  (28%) 549  (71%) 
2030 365  (14%) 507  (58%) 511  (59%) 430  (34%) 593  (85%) 
2035 372  (16%) 556  (73%) 542  (69%) 447  (39%) 638  (99%) 
2040 379  (18%) 604  (88%) 569  (77%) 459  (43%) 679  (112%) 
 
Table 16.2. Number of cancers treated in 2010, with estimates for 2025, cancer of the cervix uteri 
 2010 2025 demography 2025 Nordpred 2025 HD model 
all cases 321 361 459 480 
surgery 189 213 270 283 
chemotherapy 122 137 174 182 
radiotherapy 182 205 260 272 
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17. Cancer of the corpus uteri 
Trends 
Figure 17.1. Cancer of the corpus uteri; case numbers, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 4.5 (3.7, 5.3) 
 
Figure 17.2. Cancer of the corpus uteri; age-standardised incidence 
rate, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 2.3 (1.6, 3.1) 
There was a significant upward trend in cases of cancer of the corpus uteri of 4.5% annually between 1994 and 2010 (Figure 
17.1). There was a similar trend, a 2.3% annual increase, for age-standardised incidence rates (Figure 17.2). 
Projections 
The base of projection for the HD model was 1994-2010. HD model 4 gave the best fit. The projected number of cases from this 
model was a little below that due to demographic change alone (Figure 17.3, Table 17.1) and also below the Nordpred 
projections. The models project that case numbers will increase by 62%-90% between 2015 and 2040, with proportionate 
increases in treatment rates (Table 17.2).  
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Figure 17.3. Projected numbers of incident cases, based on M1F0 
population projections 2015-2040, with actual numbers 1995-2010: 
cancer of the corpus uteri 
 
 
 
Table 17.1.  Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the corpus 
uteri 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
 
2010        388     
2015 423  (9%) 472  (22%) 393  (1%) 352  (-9%) 434  (12%) 
2020 479  (23%) 525  (35%) 443  (14%) 399  (3%) 487  (25%) 
2025 537  (38%) 578  (49%) 495  (28%) 448  (16%) 542  (40%) 
2030 593  (53%) 631  (63%) 547  (41%) 497  (28%) 596  (54%) 
2035 643  (66%) 684  (76%) 593  (53%) 541  (39%) 644  (66%) 
2040 680  (75%) 738  (90%) 627  (62%) 573  (48%) 680  (75%) 
 
Table 17.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the corpus uteri 
 2010 2025 demography  2025 Nordpred 2025 HD model 
all cases 388 537 578 495 
surgery 370 511 551 472 
chemotherapy 52 72 77 66 
radiotherapy 182 251 271 232 
 
0
100
200
300
400
500
600
700
800
1995 2000 2005 2010 2015 2020 2025 2030 2035 2040
p
ro
je
ct
e
d
 c
as
e
 n
u
m
b
e
rs
incident cases
demographic projection
HD projection
HD 95% confidence limit
Nordpred projection
Cancer of the ovary 42 
18. Cancer of the ovary 
Trends 
Figure 18.1. Cancer of the ovary; case numbers, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 1.4 (0.7, 2.1) 
 
Figure 18.2. Cancer of the ovary; age-standardised incidence rate, 
1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2010 -0.6 (-1.4, 0.2) 
There was a significant upward trend in cases of cancer of the ovary of 1.4% annually, between 1994 and 2010 (Figure 18.1). The 
trend in age-standardised incidence rates was downwards (0.6% annually) but not statistically significant (Figure 18.2). 
Projections 
The base of projection for the HD model was 1994-2010. HD model 3 gave the best fit. The projected number of cases from this 
model was less than that due to demographic change alone but close to the Nordpred projections (Figure 18.3, Table 18.1). The 
models project that female case numbers will increase by 34%-44% between 2010 and 2040, with proportionate increases in 
treatment rates (Table 18.2).  
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Figure 18.3. Projected numbers of incident cases, based on M1F0 
population projections 2015-2040, with actual numbers 1995-2010: 
cancer of the ovary 
 
 
 
Table 18.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the ovary 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
 
2010        353     
2015 407  (15%) 392  (11%) 377  (7%) 332  (-6%) 422  (20%) 
2020 459  (30%) 416  (18%) 403  (14%) 350  (-1%) 457  (29%) 
2025 515  (46%) 439  (24%) 430  (22%) 366  (4%) 493  (40%) 
2030 569  (61%) 462  (31%) 452  (28%) 377  (7%) 527  (49%) 
2035 619  (75%) 485  (38%) 467  (32%) 380  (8%) 554  (57%) 
2040 662  (87%) 509  (44%) 474  (34%) 375  (6%) 573  (62%) 
 
Table 18.2. Number of cancers treated in 2010, with estimates for 2025: cancer of the ovary 
 2010 2025 demography  2025 Nordpred 2025 HD model 
all cases 353 515 439 430 
surgery 216 314 268 263 
chemotherapy 222 323 276 270 
radiotherapy 14 20 17 17 
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19. Cancer of the prostate 
Trends 
Figure 19.1. Cancer of the prostate; case numbers, 1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2004 9.1 (8.0, 10.3) 
2004-2010 4.4 (2.6, 6.2) 
 
Figure 19.2 Cancer of the prostate; age-standardised incidence rate, 
1994-2010 
 
 
Estimated annual percentage change (95% confidence limits) 
1994-2004 7.6 (6.6, 8.7) 
2004-2010 1.3 (-0.5, 3.0) 
There was a significant upward trend in cases of cancer of the prostate of 9.1% annually between 1994 and 2004 and of 4.4% 
annually between 2004 and 2010 (Figure 19.1). The trend in age-standardised incidence rates was similar but smaller: 7.6% 
annually between 1994 and 2004 and 1.3% from 2004 onwards (Figure 19.2). 
Projections 
The base of projection for the HD models was 2004-2010. HD model 4 gave the best fit. The projected number of cases from this 
model was similar to that due to demographic change alone but much less than the Nordpred projection (Figure 19.3, Table 
19.1). The models project that case numbers will increase by 104%-288% between 2010 and 2040, with proportionate increases 
in treatment rates (Table 19.2).  
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Figure 19.3 Incidence 1994-2010 with incidence projections 2015-
2040 based on M1F0 population projections: cancer of the prostate 
 
 
 
Table 19.1 Incidence projections 2015-2040 with % increase/decrease compared to 2010: cancer of the prostate 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
 
2010        3222     
2015 3541  (10%) 3303  (3%) 3436  (7%) 3232  (0%) 3641  (13%) 
2020 4091  (27%) 5141  (60%) 3959  (23%) 3728  (16%) 4190  (30%) 
2025 4687  (45%) 6980  (117%) 4560  (42%) 4298  (33%) 4822  (50%) 
2030 5307  (65%) 8818  (174%) 5222  (62%) 4923  (53%) 5521  (71%) 
2035 5908  (83%) 10657  (231%) 5907  (83%) 5565  (73%) 6249  (94%) 
2040 6426  (99%) 12495  (288%) 6563  (104%) 6177  (92%) 6950  (116%) 
 
Table 19.2 Number of cancers treated in 2010, with estimates for 2025, cancer of the prostate 
 2010 2025 demography 2025 Nordpred 2025 HD model 
all cases 3222 4687 6980 4560 
surgery 876 1275 1899 1240 
chemotherapy 32 42 63 41 
radiotherapy 2009 2301 3427 2239 
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20.  Cancer of the kidney and renal pelvis 
Trends 
Figure 20.1. Cancer of the kidney and renal pelvis; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 5.3 (4.6, 6.1) 1994-2010 5.4 (4.6, 6.1) 
 
Figure 20.2. Cancer of the kidney and renal pelvis; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 3.4 (2.6, 4.2) 1994-2010 2.9 (2.2, 3.7) 
There was a significant 5.3% annual upward trend in cases of cancer of the kidney and renal pelvis for females between 1994 
and 2010 and 5.4% for males (Figure 20.1). Trends in age-standardised incidence rates were smaller but also statistically 
significant: a 3.4% annual increase for females and 2.9% for males (Figure 20.2). 
 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for both males and 
females. For both females and males the HD estimates were well above those due to demographic change alone and a little 
above the Nordpred projections (Figure 20.3, Table 20.1). For males the Nordpred projections were below the 95% confidence 
limits of the HD model. The models project that female case numbers will increase by 58%-153% between 2015 and 2040, and 
male cases by 24%-124%, with proportionate increases in treatment rates (Table 20.2). 
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Figure 20.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the kidney and renal pelvis 
females males 
  
 
Table 20.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010):  cancer of the kidney 
and renal pelvis 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010      198     
2015 210  (6%) 241  (22%) 186  (-6%) 158  (-20%) 214  (8%) 
2020 238  (20%) 293  (48%) 210  (6%) 180  (-9%) 240  (21%) 
2025 268  (35%) 345  (74%) 236  (19%) 204  (3%) 268  (35%) 
2030 299  (51%) 397  (101%) 262  (33%) 228  (15%) 296  (50%) 
2035 330  (67%) 449  (127%) 288  (46%) 252  (27%) 324  (64%) 
2040 359  (81%) 501  (153%) 312  (58%) 274  (39%) 350  (77%) 
males 
2010      332     
2015 372  (12%) 383  (15%) 353  (6%) 314  (-6%) 392  (18%) 
2020 425  (28%) 456  (37%) 373  (12%) 333  (0%) 413  (24%) 
2025 481  (45%) 528  (59%) 389  (17%) 348  (5%) 430  (30%) 
2030 537  (62%) 600  (81%) 397  (20%) 355  (7%) 439  (32%) 
2035 589  (77%) 673  (103%) 403  (21%) 360  (9%) 445  (34%) 
2040 633  (91%) 745  (124%) 410  (24%) 368  (11%) 453  (36%) 
 
Table 20.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the kidney and renal pelvis 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 198 268 345 236 
surgery 146 198 254 174 
chemotherapy 23 32 41 28 
radiotherapy 23 32 41 28 
males     
all cases 332 481 528 389 
surgery 233 338 371 273 
chemotherapy 60 78 85 63 
radiotherapy 46 52 58 42 
0
100
200
300
400
500
600
1995 2000 2005 2010 2015 2020 2025 2030 2035 2040
p
ro
je
ct
e
d
 c
as
e
 n
u
m
b
e
rs
incident cases
demographic projection
HD projection
HD 95% confidence limit
Nordpred projection
0
100
200
300
400
500
600
700
800
1995 2000 2005 2010 2015 2020 2025 2030 2035 2040
p
ro
je
ct
e
d
 c
as
e
 n
u
m
b
e
rs
incident cases
demographic projection
HD projection
HD 95% confidence limit
Nordpred projection
Cancer of the bladder 48 
21. Cancer of the bladder 
Trends 
Figure 21.1. Cancer of the bladder; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 -0.2 (-1.5, 1.1) 1994-2010 -0.6 (-1.0, -0.1) 
 
Figure 21.2. Cancer of the bladder; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 -2.1 (-3.5, -0.7) 1994-2010 -2.6 (-3.2, -2.1) 
There was no significant trend in case numbers for cancer of the bladder for either females or males (Figure 21.1). Trends in age-
standardised incidence rates were significantly downwards for both sexes: 2.1% annually for females and 2.6% for males (Figure 
21.2). 
Projections 
The base of projection for the HD models for both sexes was 1994-2010. HD model 3 gave the best fit for both males and 
females. For both females and males the HD estimates were well below those due to demographic change alone (Figure 21.3, 
Table 21.1). Nordpred and HD models gave similar figures for females, but the Nordpred projections were much lower than the 
HD projections for males. There is an apparent discontinuity between the actual 1994-2010 incidence and the HD projections for 
males. The models project that female case numbers will increase by 45%-65% between 2010 and 2040 and male cases by 9%-
33%, with proportionate increases in treatment rates (Table 21.2). 
0
20
40
60
80
100
120
140
160
180
200
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
ca
se
s
observed
fitted
0
50
100
150
200
250
300
350
400
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
ca
se
s
observed
fitted
0
1
2
3
4
5
6
7
8
9
10
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
ag
e
-s
ta
n
d
ar
d
is
e
 in
ci
d
e
n
ce
 r
at
e
observed
fitted
0
5
10
15
20
25
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
ag
e
-s
ta
n
d
ar
d
is
e
 in
ci
d
e
n
ce
 r
at
e
observed
fitted
Cancer of the bladder 49 
Figure 21.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the bladder 
females males 
  
 
Table 21.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the bladder 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        119     
2015 157  (32%) 145  (22%) 148  (24%) 120  (1%) 175  (47%) 
2020 180  (51%) 156  (31%) 153  (29%) 122  (3%) 184  (55%) 
2025 207  (74%) 166  (39%) 160  (34%) 124  (4%) 195  (64%) 
2030 237  (99%) 176  (48%) 166  (39%) 125  (5%) 207  (74%) 
2035 270  (127%) 186  (56%) 171  (43%) 124  (4%) 217  (83%) 
2040 302  (154%) 196  (65%) 173  (45%) 120  (1%) 225  (89%) 
males 
2010        320     
2015 397  (24%) 290  (-10%) 413  (29%) 366  (14%) 460  (44%) 
2020 470  (47%) 302  (-6%) 417  (30%) 364  (14%) 469  (47%) 
2025 555  (73%) 314  (-2%) 424  (32%) 364  (14%) 483  (51%) 
2030 647  (102%) 326  (2%) 429  (34%) 362  (13%) 496  (55%) 
2035 745  (133%) 338  (6%) 432  (35%) 357  (11%) 507  (58%) 
2040 838  (162%) 350  (9%) 426  (33%) 344  (8%) 509  (59%) 
 
Table 21.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the bladder 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
 119 207 166 160 
surgery 75 130 104 101 
chemotherapy 35 61 49 47 
radiotherapy 27 47 38 36 
males     
 320 555 314 424 
surgery 199 345 195 263 
chemotherapy 104 145 82 111 
radiotherapy 91 108 61 82 
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22. Cancer of the brain and other central nervous system 
Trends 
Figure 22.1. Cancer of the brain and other central nervous system; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 2.4 (1.2, 3.6) 1994-2010 2.0 (1.4, 2.7) 
 
Figure 22.2. Cancer of the brain and other central nervous system; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.6 (-0.6, 1.7) 1994-2010 -0.1 (-0.7, 0.5) 
There was a significant increase in case numbers of cancer of the brain and central nervous system for both sexes: 2.4% annually 
for females and 2.0% for males (Figure 22.1). There was no significant trend in age-standardised incidence rates (Figure 22.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for females and model 1 for 
males. For both females and males the HD estimates were similar to those due to demographic change alone and for males the 
Nordpred projections were much lower than the HD projections (Figure 22.3, Table 22.1). The models project that female case 
numbers will increase by 41%-62% between 2010 and 2040 and males by 30%-149%, with proportionate increases in treatment 
rates (Table 22.2). 
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Figure 22.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: cancer of the brain and other central nervous system 
females males 
  
 
Table 22.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): cancer of the brain 
and other central nervous system  
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        183     
2015 170  (-7%) 175  (-4%) 165  (-10%) 139  (-24%) 191  (5%) 
2020 188  (3%) 200  (9%) 183  (0%) 156  (-15%) 211  (15%) 
2025 209  (14%) 224  (22%) 203  (11%) 174  (-5%) 232  (27%) 
2030 229  (25%) 248  (36%) 222  (22%) 192  (5%) 253  (38%) 
2035 249  (36%) 272  (49%) 241  (32%) 209  (14%) 273  (49%) 
2040 267  (46%) 297  (62%) 258  (41%) 224  (23%) 291  (59%) 
males 
2010        181     
2015 225  (24%) 211  (17%) 241  (33%) 205  (13%) 277  (53%) 
2020 250  (38%) 216  (19%) 270  (49%) 226  (25%) 314  (73%) 
2025 276  (52%) 220  (22%) 304  (68%) 249  (38%) 359  (98%) 
2030 301  (66%) 225  (24%) 345  (90%) 275  (52%) 414  (129%) 
2035 325  (80%) 230  (27%) 393  (117%) 305  (68%) 481  (166%) 
2040 345  (91%) 234  (30%) 451  (149%) 341  (88%) 560  (210%) 
 
Table 22.2 Number of cancers treated in 2010, with estimates for 2025: cancer of the brain and other central nervous system 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 183 209 224 203 
surgery 88 100 108 98 
chemotherapy 44 50 53 48 
radiotherapy 102 116 125 113 
males     
all cases 181 276 220 304 
surgery 87 132 105 145 
chemotherapy 69 85 68 94 
radiotherapy 164 180 144 199 
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23.  Hodgkin’s lymphoma 
Trends 
Figure 23.1. Hodgkin’s lymphoma; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 3.3 (1.7, 4.9) 1994-2010 3.5 (2.3, 4.7) 
 
Figure 23.2. Hodgkin’s lymphoma; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 1.6 (0.0, 3.2) 1994-2010 1.7 (0.6, 2.8) 
There was a significant upward trend in case numbers of Hodgkin’s lymphoma for both sexes: 3.3% annually for females and 
3.5% for males (Figure 23.1). Trends in age-standardised incidence rates followed the same pattern, with a significant 1.6% 
annual upward trend for females and 1.7% for males (Figure 23.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for both males and 
females. For both females and males the projected number of cases from this model was a little above that due to demographic 
change alone, and higher than the Nordpred projections for females (Figure 23.3, Table 23.1). The model projects that female 
case numbers will increase by 11%-30% and male cases by 41%-44%, with proportionate increases in treatment rates (Table 
23.2). 
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Figure 23.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: Hodgkin’s lymphoma 
females males 
  
 
Table 23.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): Hodgkin’s lymphoma 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010 65     
2015 57  (-12%) 53  (-19%) 67  (4%) 51  (-22%) 84  (29%) 
2020 59  (-9%) 57  (-13%) 71  (9%) 53  (-18%) 88  (35%) 
2025 62  (-5%) 60  (-7%) 73  (13%) 56  (-14%) 91  (40%) 
2030 64  (-1%) 64  (-1%) 77  (18%) 59  (-10%) 95  (46%) 
2035 67  (3%) 68  (5%) 81  (24%) 62  (-5%) 99  (52%) 
2040 69  (7%) 72  (11%) 84  (30%) 65  (0%) 103  (59%) 
males 
2010 73     
2015 73  (1%) 79  (8%) 81  (11%) 62  (-14%) 100  (36%) 
2020 78  (7%) 84  (15%) 86  (18%) 67  (-9%) 105  (44%) 
2025 81  (11%) 89  (21%) 91  (24%) 71  (-3%) 111  (52%) 
2030 84  (15%) 93  (28%) 95  (31%) 75  (2%) 116  (59%) 
2035 87  (19%) 98  (35%) 100  (37%) 78  (7%) 122  (67%) 
2040 90  (23%) 103  (41%) 105  (44%) 82  (12%) 128  (75%) 
 
Table 23.2 Number of cancers treated in 2010, with estimates for 2025: Hodgkin’s lymphoma 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 65 62 60 73 
surgery 8 8 7 9 
chemotherapy 52 49 48 59 
radiotherapy 20 19 19 23 
males     
all cases 73 81 89 91 
surgery 24 26 29 29 
chemotherapy 59 65 71 72 
radiotherapy 23 24 26 27 
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24. Non-Hodgkin’s lymphoma 
Trends 
Figure 24.1. Non-Hodgkin’s lymphoma; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 3.7 (2.8, 4.5) 1994-2010 3.9 (3.3, 4.5) 
 
Figure 24.2. Non-Hodgkin’s lymphoma; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 1.6 (0.9, 2.4) 1994-2010 1.7 (1.0, 2.3) 
The trends for non-Hodgkin’s lymphoma were similar to those for Hodgkin’s lymphoma. For females there was a significant 
upward trend in case numbers of 3.7% annually, and for males, 3.9% annually (Figure 24.1). Age-standardised incidence rates 
increased by 1.6% annually for females and by 1.7% for males (Figure 24.2). 
Projections 
The base of projection for the HD model for both sexes was 1994-2010. HD model 4 gave the best fit for both sexes. For both 
females and males the HD estimates were similar to those due to demographic change alone (Figure 24.3, Table 24.1). The 
Nordpred projections for females were above those from the HD model, while the male Nordpred projections were a little 
lower. The models project that female case numbers will increase by 68%-98% and male cases by 62%-83%, with proportionate 
increases in treatment rates (Table 24.2). 
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Figure 24.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: non-Hodgkin’s lymphoma 
females males 
  
 
Table 24.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): non-Hodgkin’s 
lymphoma 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        317     
2015 341  (8%) 359  (13%) 320  (1%) 283  (-11%) 356  (12%) 
2020 385  (22%) 413  (30%) 360  (14%) 321  (1%) 399  (26%) 
2025 433  (37%) 467  (47%) 405  (28%) 363  (15%) 446  (41%) 
2030 482  (52%) 520  (64%) 451  (42%) 406  (28%) 495  (56%) 
2035 528  (66%) 574  (81%) 494  (56%) 447  (41%) 541  (71%) 
2040 570  (80%) 627  (98%) 533  (68%) 484  (53%) 582  (84%) 
males 
2010        390     
2015 416  (7%) 411  (5%) 424  (9%) 381  (-2%) 466  (20%) 
2020 471  (21%) 455  (17%) 477  (22%) 432  (11%) 523  (34%) 
2025 529  (36%) 499  (28%) 537  (38%) 489  (25%) 586  (50%) 
2030 586  (50%) 542  (39%) 599  (54%) 547  (40%) 651  (67%) 
2035 639  (64%) 586  (50%) 658  (69%) 602  (54%) 713  (83%) 
2040 688  (76%) 630  (62%) 713  (83%) 654  (68%) 771  (98%) 
 
Table 24.2 Number of cancers treated in 2010, with estimates for 2025: non-Hodgkin’s lymphoma 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 317 433 467 405 
surgery 54 74 80 69 
chemotherapy 200 273 294 255 
radiotherapy 46 63 68 59 
males     
all cases 390 529 499 537 
surgery 92 125 118 127 
chemotherapy 260 331 312 336 
radiotherapy 93 105 99 106 
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25. Leukaemia 
Trends 
Figure 25.1. Leukaemia; case numbers, 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 1.7 (0.8, 2.7) 
1994-2004 4.6 (3.3, 5.9) 
2004-2010 -1.1 (-3.5, 1.4) 
 
Figure 25.2. Leukaemia; age-standardised incidence rates 1994-2010 
females males 
  
Estimated annual percentage change (95% confidence limits) Estimated annual percentage change (95% confidence limits) 
1994-2010 0.1 (-0.9, 1.2) 
1994-2004 3.1 (1.8, 4.3) 
2004-2010 -4.1 (-6.6, -1.6) 
There was a significant upward trend in leukaemia case numbers for females of 1.7% annually. For males there was a significant 
upward trend of 4.6% annually between 1994 and 2004, with no significant change in case numbers from 2004 onwards (Figure 
25.1). There was no significant change in female age-standardised incidence rates between 1994 and 2010, while for males 
there was a 3.1% annual increase between 1994 and 2004, and a 4.1% annual fall after 2004 (Figure 25.2). 
Projections 
The base of projection for the HD models for females was 1994-2010 and for males 2004-2010. HD model 3 gave the best fit for 
both sexes. For females there was reasonable agreement between the HD and Nordpred model, but for males the projected 
numbers were quite different (Figure 25.3, Table 25.1). The HD model projects a fall in cases, while Nordpred projects an 
increase; both were below the increase based on demographic change. The models project that female case numbers will 
increase by 31%-92% between 2015 and 2040, while male cases are projected to increase by 39% (Nordpred) or decrease by 
57% (HD), with proportionate changes in treatment rates (Table 25.2). 
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Figure 25.3. Projected numbers of incident cases, based on M1F0 population projections 2015-2040, with actual numbers 1995-
2010: leukaemia 
females males 
  
 
Table 25.1. Projected numbers of incident cases 2015-2040 (with % increase/decrease compared to 2010): leukaemia 
 demography only Nordpred HD projections 
lower 95% HD 
confidence limit 
upper 95% HD 
confidence limit 
females 
2010        201     
2015 225  (12%) 226  (12%) 197  (-2%) 164  (-18%) 230  (14%) 
2020 251  (25%) 258  (28%) 210  (4%) 171  (-15%) 248  (23%) 
2025 282  (40%) 290  (44%) 224  (11%) 178  (-11%) 270  (34%) 
2030 314  (56%) 322  (60%) 239  (19%) 184  (-8%) 293  (46%) 
2035 347  (72%) 354  (76%) 252  (25%) 188  (-7%) 317  (57%) 
2040 379  (88%) 386  (92%) 263  (31%) 188  (-7%) 338  (68%) 
males 
2010        286     
2015 349  (22%) 293  (3%) 265  (-7%) 219  (-24%) 312  (9%) 
2020 398  (39%) 314  (10%) 229  (-20%) 171  (-40%) 287  (0%) 
2025 453  (59%) 335  (17%) 198  (-31%) 132  (-54%) 265  (-7%) 
2030 511  (79%) 355  (24%) 171  (-40%) 99  (-66%) 244  (-15%) 
2035 567  (98%) 376  (31%) 147  (-49%) 71  (-75%) 222  (-22%) 
2040 620  (117%) 396  (39%) 124  (-57%) 49  (-83%) 198  (-31%) 
 
Table 25.2 Number of cancers treated in 2010, with estimates for 2025: leukaemia 
 2010 2025 demography  2025 Nordpred 2025 HD model 
females     
all cases 201 282 290 224 
surgery 2 3 3 2 
chemotherapy 89 124 128 99 
radiotherapy 12 17 17 13 
males     
all cases 286 453 335 198 
surgery 6 9 7 4 
chemotherapy 164 213 157 93 
radiotherapy 26 30 22 13 
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26. Discussion  
26.1 Summary 
This report shows, as have previous projections of cancer numbers by the Registry [17, 18], that the number of 
new cancers in Ireland is expected to increase significantly in the next three decades. Based only on changes in 
demography, the total number of new invasive cancers will almost double between 2010 and 2040, from 
28,480 to 55,991. In the decade 2010-2020 alone, we expect a 25% increase in new cancer cases, with a 
proportionate increase in the numbers of treatments. 
With the exception of leukaemia in males, the number of cancers is projected to increase for all sites between 
2010 and 2040 (Figure 26.1). 
The most rapidly increasing cancers in coming decades are likely to be those of skin—both melanoma and non-
melanoma—in both sexes. Cancers of the upper gastrointestinal tract—oesophagus, pancreas and 
hepatobiliary tract—are also expected to increase by over 100% by 2040.  
Of the other common cancers  
 cancers of the colon and rectum are projected to increase largely in line with demographic change, by 
120%-130% between 2010 and 2040;  
Figure 26.1. Projected percentage increase in number of cancer cases 2010-2040, by cancer site and sex 
females males 
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 lung cancer incidence is rising more rapidly in females than in males and by 2040 the rate is projected 
to increase by 136% in females (Nordpred) and 52% in males;  
 female breast cancer is difficult to project, due to recent short-term variations in incidence trends, 
but is expected to increase by about 130% between 2010 and 2040. However one HD model projects 
a much slower rate of increase for females; 
 future trends in prostate cancer rates are unclear; the HD models project an increase of 104% in new 
cases by 2040, while Nordpred projects an increase of 288%; the latter, which is based on the rapid 
increase in rate in the early 2000s, driven by PSA testing, seems implausible;  
 the models for cancer of the bladder and for leukaemia in males were heterogeneous, and future 
trends in these are difficult to project. 
26.2 Comparison with previous projections 
Table 26.1 compares the projections in this report to those made in 2008 [18]. For all invasive cancers 
combined, the projections of all models in this report were lower than those made in 2008. This was largely 
due to the revision of CSO population projections following the 2011 census. The difference in projected case 
numbers was larger for males than for females, probably due to the rapid increase in prostate cancer in the 
late 1990s and early 2000s, which had not levelled off when the previous projections were made. As the 
definition of “head and neck” cancers differed between the two reports, the figures are not comparable. 
Projections for oesophageal and stomach cancers for females, and for stomach cancer in males, are higher 
than in the previous reports, but lower for oesophageal cancer in males. Projections for colorectal cancer are 
slightly lower than in the previous report. Melanoma and non-melanoma skin cancer projections were 
variable, some higher and some lower than the previous figures. Projections for cancer of the kidney and renal 
pelvis in females were well below those in the previous report; the expected increase in renal cancer 
incidence, probably due to incidental findings on imaging [25-27], was not sustained. Projections for cancers of 
the bladder, brain and CNS and for lymphoma were all a little lower than previous projections. Projections for 
prostate cancer or leukaemia in males are not in Table 26.1 as projections for these were not made in 2008.  
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Table 26.1. Comparison of 2008 projections [18] to those in this report 
 2008 report demographic projections Nordpred projections HD projections 
  projected cases 
% of 2008 
projections 
projected cases 
% of 2008 
projections 
projected cases 
% of 2008 
projections 
females        
all invasive cancers 27404 22368 82% 26693 97% 22580 82% 
all invasive excluding 
NMSC
1
  
19918 15576 78% 17813 89% 13397 67% 
head and neck
2
 194 245 126% 358 185% 241 124% 
oesophagus 202 271 134% 254 126% 218 108% 
stomach 209 378 181% 287 137% 231 111% 
colorectal
3
 2128 1976 93% 2019 95% 1942 91% 
pancreas 565 482 85% 498 88% 442 78% 
lung 2642 1694 64% 2022 77% 2429
7
/1538
8
 92%
7
/58%
8
 
melanoma of skin 1170 713 61% 940 80% 1269 108% 
non-melanoma skin 7504 6791 90% 9070 121% 11143 148% 
breast 4833 4514 93% 5615 116% 6639
7
/4289
8
 137%
7
/89%
8
 
gynaecological
4
 2464 1634 66% 1725 70% 1602 65% 
kidney 578 330 57% 449 78% 288 50% 
bladder 216 270 125% 186 86% 171 79% 
brain and CNS
5
 357 249 70% 272 76% 241 68% 
lymphoma
6
 919 595 65% 642 70% 575 63% 
leukaemia 384 347 90% 354 92% 252 66% 
        
males        
all invasive cancers 36441 28855 79% 30824 85% 32026 88% 
all invasive excluding 
NMSC  
27378 19784 72% 20097 73% 21500 79% 
head and neck 884 668 76% 779 88% 649 73% 
oesophagus 613 501 82% 465 76% 571 93% 
stomach 372 699 188% 531 143% 457 123% 
colorectal 3409 2923 86% 2521 74% 3067 90% 
pancreas 451 524 116% 525 116% 581 129% 
lung 2104 2610 124% 1836 87% 2132 101% 
melanoma of skin 1153 622 54% 808 70% 1381 120% 
non-melanoma skin 17181 9071 53% 10974 64% 18407 107% 
kidney 445 589 132% 673 151% 403 91% 
bladder 529 745 141% 338 64% 432 82% 
brain and CNS 539 325 60% 230 43% 393 73% 
lymphoma 1314 726 55% 684 52% 758 58% 
Notes:  
1. NMSC: non-melanoma skin cancer 
2.  Head and neck includes larynx in this report but not in 2008.  
3. Total of projections for colon and rectum.  
4. Total of cervix, corpus uteri and ovary from this report; included some rare additional sites in 2008.  
5. CNS: central nervous system 
6. Total of projections for Hodgkin’s and non-Hodgkin’s lymphoma in this report 
7. HD model 1 
8. HD model 4 
Discussion 62 
26.3 Strengths and limitations 
The strengths of the approach used here are that the methods are robust and widely used, use all the available 
data and make a minimal number of assumptions about the underlying trends. We also, for the first time, 
provide estimates of future demand for cancer treatments, with the caveat that these depend on the stability 
of treatment patterns into the future. 
The most significant limitation of the approach is that it assumes that current incidence trends will continue 
unchanged into the future. The use of projection models can be useful in assessing future needs for cancer 
services and, in some situations, for estimating the impact of measures to reduce cancer incidence. However, 
models simplify what is a complex combination of changing risk factors, diagnosis, screening and classification. 
Although historic trends can be fitted using more complex models than those shown here [28] these models 
also make more assumptions about the continuity of trends into the future. Even over the relatively short 
period covered by the National Cancer Registry, incidence trends for a quite a few cancers have changed 
significantly and therefore the assumption of continuity of trends into the future is not very firmly based. The 
methods used here are similar to those in previous projections [18] and may be partially validated by 
comparing previous projections with current data (Figures 26.2, 26.3). In general, the previous projections for 
2010 are close to the actual 2010 incidence figures for most sites, although the projections slightly under-
estimated the increase in cancer numbers for the majority of sites. For males there was a slight under-
estimation of numbers of cancers of lung, stomach and melanoma and, for females, an under-estimation of 
numbers of non-melanoma skin cancers and an over-estimation of brain and CNS cancer. However this 
comparison is for only a few years following the publication of the previous projections and the validity of 
longer-term projections is less secure. 
Another limitation of modelling is the sometimes large discrepancies between the results of different 
modelling approaches to the same data. Different models may project quite different trends, as can be seen in 
this report for cancers of the lung, female breast, bladder, and for leukaemia in males. For most cancers, case 
numbers by age group and year are relatively sparse and subject to considerable year-to-year variation. 
Models based on age-specific rates may place too much reliance on apparent trends in these rates; on the 
other hand ignoring these would be mistaken if there are real differences in trend between different age 
groups. Even when rates are modelled for all age groups combined, an increase in case numbers may fit an 
exponential growth curve closely, although long-term exponential growth in cancer rate is extremely unlikely. 
Consequently, less reliance can be placed on projections for 20 years than on those for 10. It must also be 
remembered that for some cancers, the period which was the basis of projection was less than 10 years. The 
Nordpred model has the advantage of using a fixed power relationship for all cancers, and avoiding the 
exponential trends sometimes fitted by the HD models.  
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Figure 26.2. Actual and projected
1
 (with 95% confidence limits) 
case numbers 2010 
Figure 26.3. Projected case numbers
1
 (with 95% confidence 
limits) as a percentage of actual case numbers, 2010 
females females 
  
males males 
  
1. Projected case numbers are taken from “Cancer projections 2005-2035”, National Cancer Registry, 2008 [18]. 
For a number of cancers, there were substantial differences between the HD and Nordpred projections. There 
were a number of possible reasons for these discrepancies.  
1. Nordpred software needs a minimum of three 5-year periods and always used the entire period 1996-
2010 as the base of projection, even when there were changes in trend during that period. HD 
projections used a shorter base of projection when there were recent significant changes in incidence 
rate. Nordpred is therefore more reliable when trends were stable over the entire period. 
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2. The HD models which fit best in most cases (models 3 and 4) did not fit trends separately to each age 
group, whereas Nordpred does, so in cases where the trends for younger patients were different from 
those for older patients, the models differed. This may be seen as a weakness of the HD model, but 
the number of cases in each age group is small and the modelled trends by age group are not 
necessarily reliable.  
3. For a small number of sites, the HD log-linear age-period model gave the best fit, although 
exponential growth in cancer numbers is implausible over long periods. In those cases, the Nordpred 
estimates are probably more reliable, especially in the longer term.  
As a consequence, although statistical tests for choosing the best fit of a model to the historic data are a 
reasonable guide, there is some degree of subjectivity in the final choice of model. For this reason we have 
offered a number of possible models in this report, where the best choice was not obvious. A review of 
different methods for case projections has suggested that Nordpred projections may be more reliable in the 
longer term [22, 29], but this has not yet been verified against real data.  
As population projections are now available up to 2040 we have attempted to make some projections of 
cancer case numbers for the same period. However, these need to be viewed with caution, as there have been 
significant changes in incidence trends for many cancers in the past two decades, as well as documented 
changes in risk factor prevalence. Projections for the next decade (2015-2025) are likely to be reliable; our 
comparison of previous projections to actual incidence supports this. For longer periods, the best we can hope 
for is that projections can give some general indication of future cancer burden. As few cancers currently have 
a decreasing trend in incidence rate, demographic projections tend to be the most conservative and provide a 
“best-case” scenario for most cancers. 
26.4 Determinants of changing cancer incidence 
Trends in cancer incidence are determined principally by two elements: population change and changes in 
exposure to risk factors. More information is usually available on population trends, which are readily 
incorporated into projections of cancer numbers. A number of projections have been attempted on the basis 
of current and projected changes in risk factor prevalence [30-34] but there is a long lag period, estimated at 
15-20 years for solid tumours, between changes in risk factor prevalence and the development of the 
associated cancers, so these models are difficult to verify. Most projections are based on the assumption that 
risk factor prevalence tends to be stable over long periods of time, changes only slowly and can be modelled 
indirectly from changes in age-standardised rate. While this may be valid for some risk factors, others, such as 
obesity, are increasing rapidly. Case numbers may also be affected by a number of other factors: screening 
programmes, changes in medical practice leading to the discovery of more incidental cancers, advances in 
diagnostic procedures or changes in histological classification and changes in the completeness of registration. 
These may lead to short-term changes in incidence which are difficult to incorporate into models and the 
assumption is generally made that, apart from screening programmes, their impact is slight. 
Demographic change 
The models of population change provided by the CSO make a number of assumptions with regard to 
mortality, migration and fertility. Only the first of these is likely to have any major impact on future cancer 
numbers, as the others affect the younger population, which has a low cancer incidence. The projections used 
here project a continuing improvement in life expectancy of approximately one year of life for each five 
calendar years between 2010 and 2046. However the increase in life expectancy at birth has been more rapid 
than this since the late 1990s, and it is possible that the number of older people in the population will increase 
more rapidly than is projected in the CSO figures. This would result in a larger number of cancer cases than 
projected here. 
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Risk factor prevalence 
Four risk factors have been shown to determine the majority of the attributable risk of cancer (excluding non-
melanoma skin cancer) in the UK [35]—tobacco [36], diet (including energy balance, obesity and physical 
activity) [37], alcohol [38] and reproductive factors [39, 40]. No equivalent calculations have been done for 
Ireland, but given the similarity in lifestyle between the populations of Ireland and the UK, it is reasonable to 
assume that the distribution and prevalence of attributable risks due to these major factors are similar. In 
addition to these general risk factors, we must also consider some cancer-specific causes—UV light for skin 
cancers, H pylori for stomach cancer and HPV for cervical cancer. 
Tobacco 
Although reliable long-term data on smoking prevalence are difficult to obtain for Ireland, it is estimated that 
smoking prevalence in males was 35% in 1986-1987, falling to 32% by 1998, while, for females, prevalence 
remained at 31% throughout the 1990s [41, 42]. The SLÁN surveys [43] reported a smoking prevalence of 34% 
in males in 1998, 27% in 2002 and 31% in 2007 and 32%, 27% and 27% in females in the same period. Data 
from the Office of Tobacco Control (OTC) shows a prevalence of 30% for males and 28% for females in 2002, 
falling to 25% in males and 22% in females in 2010 [44, 45] (Figure 26.4). Overall, there has been a fall of about 
9% in smoking prevalence for males and of about 8% for females since 1986. The rate of decrease seems more 
rapid since about 2003. The HSE/OTC data show a rapid decline in smoking prevalence in younger adults, 
which is likely to be sustained. 
Diet and energy balance 
Obesity and lack of physical exercise are probably more important in cancer aetiology than individual dietary 
components [46-48]. The most comprehensive data on diet, exercise and energy balance in Ireland come from 
the SLÁN surveys [45]. These show a steady increase in BMI and weight from 1998 to 2007. The percentage 
whose self-reported weight was in the “over-weight” or “obese” range increased from 51% to 59% (males) and 
35% to 41% (females) in the same period. The largest increases in weight and BMI were in the oldest age 
group. Most age groups, apart from the oldest, reported a fall in their mean energy intake over this period, 
with falls in fat and carbohydrate intake. The percentage reporting that they had taken no exercise in the 
previous week also fell between 1998 and 2007. These reports are somewhat inconsistent with the BMI data, 
but point to the possible adoption of a healthier lifestyle. 
Figure 26.4 Cigarette smoking in Ireland 1998-2010 
males females 
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Alcohol 
Alcohol consumption per adult seems to have peaked in 2000-2002 at over 14 litres alcohol/adult/year and 
has fallen slightly since then (Figure 26.5) [14]. Patterns of drinking may also have changed [14]. The number of 
heavy drinkers has fallen considerably in the younger age groups but much less in those 45 and over (Figure 
26.6) [49]. 
Figure 26.5. Alcohol consumption(litres of alcohol per person), 
selected countries and OECD average 1990-2011 
Figure 26.6. Percentage of drinkers who consumed alcohol above 
the recommended weekly limit in the previous 12 months 1998, 
2020 and 2007 
  
 
 
Reproductive life 
Parity, age at first birth, age at menarche and age at menopause are among the most important risk factors for 
breast cancer, as they are markers of oestrogen exposure. There is little information on the last two in Ireland. 
Mean age at menarche appears to have decreased from 13.5 in 1986 to 12.5 in 2007 [50]; no information 
could be retrieved on trends in age at menopause. Parity has fallen from 3.4, for females in the 1940 birth 
cohort, to 1.7 for those in the 1969 cohort (data from 2006) [51]. In the 2011 census, females aged 70+ 
reported 4.4 live births over their reproductive life, compared to 2.9 for those aged 50-54 [52]. Age of the 
mother at first birth has risen from 24.5 in 1950-1960 to 28.6 in 2002-2011 [53]. All of these trends suggest 
increasing lifetime oestrogen exposure. 
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26.5 Trends by cancer site 
All invasive cancer sites combined 
Of the four most important modifiable cancer risk factors—tobacco consumption, alcohol abuse, obesity and  
changes in reproductive and hormonal patterns—the first two are decreasing in prevalence in Ireland, while 
the others are increasing. The overall impact of these changes on cancer trends is difficult to predict, but early 
reductions in incidence rates seem unlikely. The number of cases of invasive cancer is projected to increase 
from 28,480 in 2010 to almost 60,000 in 2040, based on demographic change alone, in the absence of any 
change in incidence rates. Similar trends can be seen if non-melanoma cancers of the skin are excluded. A 
worrying trend is the greater rate of increase in tobacco-related cancers in females. 
It is estimated that the interval between initiation of a solid tumour and its diagnosis is 15 to 20 years, so most 
of the projected increase between now and 2030 has been determined by prior exposures and will not be 
affected by future preventive measures. Changes in lifestyle in the past decade are unlikely to have yet 
manifested in incidence changes, but the changes in tobacco and alcohol consumption should manifest as 
some reduction in cancer incidence rates in the next few decades. 
Tobacco-related cancers 
Tobacco smoking has been implicated as a causal factor in many cancers [54]. However, the estimated relative 
risk due to smoking ranges widely, from 14.6 for laryngeal cancer in males to 1.2 for colorectal (Table 26.2). 
Table 26.2. Estimated relative risks (RR) for current smokers aged 35 compared with never-smokers [36] 
cancer males females 
larynx 14.6 13.0 
lung 21.3 12.5 
oesophagus 6.8 7.8 
oral cavity and pharynx 10.9 5.1 
urinary bladder 3.0 2.4 
pancreas 2.2 2.2 
ovary (mucinous) — 2.1 
stomach 2.2 1.5 
liver 2.3 1.5 
cervix — 1.5 
kidney and renal pelvis 2.5 1.5 
colon–rectum 1.2 1.3 
acute myeloid leukaemia 1.9 1.2 
The estimated increase in tobacco-related cancers in Ireland between 2010 and 2040 is, in general, greater for 
females than for males (Table 26.3). Cancer of the lung is projected to increase by 95%-196% in females and by 
72%-121% in males, cancer of the oesophagus by 84%-140% in females and 112%-160% in males and cancer of 
the bladder by 45%-65% in females and 9%-33% in males. The projections for cancer of the head and neck are 
inconsistent—the HD model projects a larger relative increase in incidence in males, while Nordpred projects a 
larger increase in females. The overall projected increase between 2010 and 2040 in the number of tobacco-
related cancers listed in Table 26.2 is 110%-115% for females, and 83%-91% for males; these cancer sites 
represent approximately half of all invasive cancers, excluding non-melanoma skin.  
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Table 26.3 Projected % increase 2010-2040 in tobacco-related cancers: HD and Nordpred models 
                 females           males 
 HD Nordpred HD Nordpred 
head and neck
1
 46% 128% 66% 108% 
oesophagus 84% 123% 160% 112% 
stomach 32% 74% 27% 59% 
colon 116% 117% 156% 104% 
rectum 83% 110% 105% 77% 
liver, biliary tract and gallbladder 127% 148% 113% 155% 
pancreas 140% 172% 152% 129% 
lung 196% 136% 72% 52% 
cervix 77% 88% - - 
ovary 34% 44% - - 
kidney 58% 153% 24% 124% 
bladder 45% 65% 33% 9% 
all cancers listed above 110% 115% 91% 83% 
Note: The category “head and neck” corresponds largely to cancers of the oral cavity, pharynx and larynx in 
Table 26.2. 
Cancers of the head and neck 
Cancers of the head and neck are a heterogeneous group, but tobacco and alcohol are important in their 
aetiology [55, 56]. HPV infection is considered a causal factor for cancers of the oropharynx [57], but has only a 
minor effect on overall head and neck cancer incidence [58]. The overall trend resembled that for other 
primarily tobacco-related cancers, with an increase in rate for females, but not males. This is reflected in the 
larger projected increase for females (48%-108% between 2010 and 2040) than for males, which was greater 
than projected from demographic change alone.  The variability in trends for males has resulted in the 
Nordpred projection being higher than that of the HD model because, although there was no statistically 
significant trend in rates for males, the aggregate rate for males in 2006-2010 was higher than that for 1996-
2000. 
Cancer of the oesophagus 
The main risk factors for cancer of the oesophagus are smoking and obesity [59, 60]. Adenocarcinoma of the 
oesophagus is increasing in incidence, while squamous carcinoma is decreasing [23] and the interaction of 
these trends has led to a modest projected increase in incidence, slightly below the demographic trend for 
females and slightly above it for males. 
Cancer of the stomach 
Helicobacter pylori is the most firmly established risk factor for this cancer in European populations [61, 62]. In 
common with most other European countries [63] cancer of the stomach in Ireland is decreasing in incidence. 
There are no reliable data on trends in prevalence of H pylori in Ireland, and the studies carried out have been 
on small and unrepresentative population samples. However, as the incidence of stomach cancer in Ireland 
remains 50% above that in most Nordic countries [63] it seems reasonable to expect that the incidence will 
continue to decrease as projected. The rate of this decrease is uncertain, as there appears to have been some 
levelling off of the downward trends in rate for both males and females, as evidenced by the differences 
between the Nordpred and HD projections.  
Cancer of the colon, rectum and anus 
Dietary factors, including consumption of fruit, vegetable and fibre, are known to be protective against cancers 
of the colon and rectum, while obesity, red meat consumption and lack of physical activity are known to be 
causative factors [64-66]. Screening (which has not yet been introduced on a full population basis in Ireland) 
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may, in the longer term, also result in a reduction in incidence [67, 68]. The incidence rate for these cancers 
has remained fairly constant since 1994, with a small increase in colon cancer in males. Consequently, the 
projected figures are very close to those expected from demographic change. Similar trends are seen in other 
European countries, although the Netherlands has had a recent increase in incidence [63]. 
Cancer of the liver, biliary tract and gallbladder 
As previously reported, there has been an increase in cholangiocarcinoma incidence in Ireland and other 
countries [24]. The reasons for this are unclear and some of the increase may be due to improved diagnostic 
localization. Alcohol abuse is the main aetiological factor for hepatocellular carcinoma, with chronic infective 
hepatitis being a secondary factor [57]. Viral infection, diabetes and cholelithiasis are possible risk factors for 
extrahepatic cholangiocarcinoma [69, 70]. All projections suggest a similar increase in rate over the next 25 
years, of approximately 2-fold. 
Cancer of the pancreas 
Tobacco and heavy alcohol intake are important causative factors for cancer of the pancreas [54]. However, 
unlike some other tobacco-related cancers, female pancreatic cancer rates are not increasing, while there has 
been a small increase in male rates. However, only about 30% of pancreatic cancers are histologically verified 
and median survival is only 3 months of diagnosis, so diagnostic accuracy is not as high for this cancer as it is 
for others [71] and incidence rates are consequently less reliable. Because of the absence of any time trends in 
the historic data, projections based on the Nordpred, HD and demographic models were all similar. 
Cancer of the lung 
Tobacco is the cause of the overwhelming majority of lung cancer, although radon is considered to contribute 
about 8% of the attributable risk [72]. There has been a long-term increase in female lung cancer incidence 
rates since 1994; however, there has been no increase between 2004 and 2009. Given the gradual decrease in 
female smoking rates in the 1990s, there is likely to be an eventual levelling-off in female incidence rates. For 
females, the consequence is that three quite different estimates of future case numbers fit the models 
reasonably well, with estimates of cases in 2040 ranging from 1693 (HD model 4) to 2830 (HD model 1). The 
Nordpred model, which assumes the greatest stability of trends over time, gives an estimate of 2260 female 
cases in 2040, and this intermediate estimate is the most plausible, although possibly an over-estimate if we 
are seeing the start of a levelling–off in rate. Male rates show a long-term decrease but, again, no real change 
between 2004 and 2010. For males the HD model gives a higher estimate than the Nordpred model, which lies 
outside the 95% confidence limits of the HD model.  
Melanoma of skin 
The primary risk factor for melanoma is UV exposure (including sunbeds), with burning in childhood and 
adolescence probably more important than total sun exposure [73, 74]. The recent rate of increase in 
incidence rates for melanoma of skin is greater than for most other common cancers, and almost twice as fast 
for males as for females. The HD models, which are based on more recent trends, project much higher 
numbers than either the Nordpred or demographic models. 
Non-melanoma cancer of skin 
The primary risk factor for non-melanoma cancer of the skin is UV exposure (including sunbeds) [73, 74]. 
Incidence rates have been increasing since 2001 for both males and females at about 3% annually. Evidence 
suggests that this is mainly due to recreational exposure [75]. For females the HD and Nordpred models give 
similar results, but for males the Nordpred estimates are much lower than those given by the HD model. 
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Female breast cancer 
The main risk factors for breast cancer are early age at menarche [76], late age at first birth [77] low parity [76, 
77], late menopause [76] and breastfeeding [78]. Obesity [79] and alcohol consumption [80] also significantly 
increase the risk of female breast cancer. The Nordpred projections lie between the two HD projections for 
female breast cancer. Projections are difficult for this cancer because of the short-term effects of the 
introduction of a national breast screening programme, which was rolled out in two phases over a relatively 
long period between 2000 and 2009. Prior to the screening programme there was an upward trend in both 
numbers and incidence rate, which would be expected from the trends in earlier menarche and reproductive 
patterns previously described. It seems likely that this will continue, giving breast cancer numbers somewhat 
above the demographic model. The Nordpred projection, which is based on long-term trends, is the most 
plausible under these circumstances. 
Cancer of the cervix uteri 
The main risk factors for cancer of the cervix are HPV infection, smoking, parity and oral contraceptive use [54, 
57]. Changing sexual behaviour and an increase in HPV prevalence are probably the most important factors 
influencing recent trends in Ireland. However, the incidence is also affected by screening activity. Incidence 
tends to rise at the beginning of screening, and opportunistic screening may also increase incidence. However, 
a well-organised population-based programme would be expected to reduce incidence [81]. Although the 
national screening programme has only recently been introduced in Ireland, opportunistic screening has been 
occurring for some time at quite a high level. Both the HD and Nordpred projections are similar and suggest a 
doubling in case numbers between 2010 and 2040. However, the recent introduction of the national screening 
programme, CervicalCheck, should reduce these numbers. 
Cancer of the corpus uteri 
Obesity is the best-attested risk factor for cancer of the corpus uteri [82]. The projected increase in numbers 
and rate is consistent with the reported increase in obesity in the population. The Nordpred projections are 
higher than those from the HD model and the demographic projections lie between the two. 
Cancer of ovary 
A number of reproductive and hormonal risk factors have been identified for ovarian cancer. The risk of this 
cancer reduces with parity, breast-feeding, tubal ligation, hysterectomy and oral contraceptive use (for 5 years 
or more), but other aspects of the aetiology are still not well understood [83]. The trend in incidence rate has 
been downward since 1994 and the projected increase in numbers is small. Both the HD and Nordpred models 
suggest an increase of 34%-44%, much less than the demographic projections. 
Cancer of prostate 
Age, race, and a family history of prostate cancer are the only established risk factors for prostate cancer. 
Androgens, diet, physical activity, sexual factors, inflammation, and obesity have been implicated, but their 
roles remain unclear [84]. There was a rapid increase in prostate cancer cases in the 1990s and early 2000s, 
due to the widespread use of PSA testing [85], but this trend began to level off around 2004 and return to the 
rate of increase seen in the early 1990s. Due to the large variations in trend in the past two decades, the 
projections for this site vary widely and cannot be regarded as currently very reliable. 
Cancer of kidney and renal pelvis 
Smoking and obesity are the main risk factors for cancer of the kidney [86, 87] although incidental discovery 
on abdominal imaging is also thought to contribute to rising incidence, especially in females [27, 88]. Cancer of 
the kidney and renal pelvis is increasing in incidence at a rate greater than that for all cancers combined, and 
there is consequently a high number of projected cases. For females, the HD and Nordpred projections gave 
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similar results, but for males the Nordpred projections were much lower than those from the HD method, and 
not much above the demographic projections. This may have been due to the relatively low incidence rates in 
2006 and 2007, and the HD projections are probably more reliable. 
Cancer of bladder 
Smoking accounts for about 50% of all bladder cancers [89]. Occupational exposures are also risk factors, while 
the role of diet and environmental pollution are unproven [90]. The incidence of cancer of the bladder is 
decreasing for both males and females. The Nordpred and HD projections were consistent for females, but 
different for males and much lower than those for demography only. 
Cancer of brain and other central nervous system 
Cancers of the brain and other central nervous system are a heterogeneous group, with no common 
aetiological factors. There was no significant trend in incidence for either females or males. For females the 
demographic, Nordpred and HD projections were very similar. For males, the demographic projections lay 
between the HD and Nordpred projections. The Nordpred method projected almost no increase in male brain 
cancer numbers over the next 20 years. 
Hodgkin’s lymphoma 
The main aetiological agent for Hodgkin’s lymphoma is Epstein-Barr virus, but the role of this common 
infection in the causation of the disease is unclear [91]. The number of incident Hodgkin’s lymphomas is small 
and there are upward trends for both males and females. For females the HD projections were higher than 
either Nordpred or demographic projections, while for males the HD and Nordpred projections were similar. 
Non-Hodgkin’s lymphoma 
The aetiology of non-Hodgkin’s lymphoma is poorly understood, with the only established risk factors being 
infection and immune dysregulation [92]. Epidemiological studies have suggested that certain environmental 
and occupational exposures and lifestyle factors may be associated with the risk of NHL; however, these 
factors are uncommon and can explain only a small portion of NHL cases. The upward trends in non-Hodgkin’s 
lymphoma are almost identical to those for Hodgkin’s lymphoma. The projections for HD, Nordpred and 
demographic models were all quite similar. 
Leukaemia 
About 50% of leukaemias are of lymphoid cell type and 25% are myeloid [93]. No important common 
aetiological factors have been identified for either cell type. Recent leukaemia trends in males are downwards, 
while there was no significant trend for females. Most of the decrease has been in lymphoid leukaemias and 
those described as “unspecified” [93]. Nordpred and demographic projections were similar for females, and 
higher than the HD projections. For males, the projections varied widely, with the demographic projections 
being highest, and the HD projections showing a 50% fall in case numbers by 2040.
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27. Conclusions 
All the models described here project an increase of around one-third in cancer cases in the decade 2015-
2025. For females the Nordpred estimate was of an increase of 41% while the HD and demographic 
projections were close to 30%. For males the figures were a little higher, ranging from 33% (demography) to 
47% (Nordpred). Almost all cancer types are expected to increase in number. This almost inevitable increase 
will place additional burdens on the cancer services, for diagnosis, treatment, support and aftercare.  
We have assumed that current trends in incidence will continue into the near future. However, we have seen 
how, for three common cancers—breast, cervix and prostate—screening has led to a considerable increase in 
the number of diagnosed cancer cases; screening for colorectal cancer has recently begun and it is to be 
expected that novel methods of screening for other cancers will appear in the next decade. While some 
screening may eventually bring about a reduction in health service costs, screening will initially increase case 
numbers and costs above what might be expected from natural increase. The introduction of each new 
screening method must therefore be preceded by a careful cost-utility analysis. 
With the ageing of the population, and improved life expectancy, the median age of cancer patients at 
diagnosis will increase. For all invasive cancers combined the percentage of patients aged over 70 is expected 
to increase, for females, from 31% in 2015 to 44% in 2025 and, for males, from 40% to 51%. As a result there 
will not only be more cancer patients, but they will be older on average. This older population will have 
different needs, responses to treatment and susceptibility to side-effects. Clear guidelines on the assessment 
and treatment of older patients are urgently needed. Clinical trial data on older patients remains quite limited 
and there is a tendency to under-estimate the capacity of fit older patients to tolerate curative treatments. 
The combination of increasing incidence and improving survival of cancer patients will place a growing burden 
of follow-up on the cancer services. With greater life expectancy and better survival, the number of prevalent 
cases is increasing even faster than incident cases, with clear consequences for surveillance, support and 
aftercare services. 
A further challenge is the growing availability and use of ever more sophisticated and expensive targeted 
therapy. The proportion of patients having chemotherapy in Ireland increased by 13% between 2000-2004 and 
2005-2009, and it is noticeable that most of this increase was in cancers where chemotherapy levels were 
previously quite low [94]. While the greater efficacy and more widespread use of chemotherapy has 
contributed to an improvement in survival [94, 95], the high cost of some therapies, particularly those for 
advanced disease, will need to be balanced against the benefits to the patient, and also against other priorities 
in cancer care. These decisions will become increasingly difficult as more therapies become available and life 
expectancy increases; they cannot be based on the length of survival alone, but also on the quality of this 
survival. The development of expensive therapies and screening interventions has driven a programme of 
research at the Registry into the economics of cancer care [96-99] both from the patient and the provider 
perspective. We have, for instance, investigated the cost-effectiveness of different methods of reducing 
morbidity and mortality from colorectal cancer [100]; is it best to set up a prevention programme, to establish 
a screening programme, or to provide more surgery, chemotherapy and radiotherapy?  
Recognising the importance of outcome measures other than length of survival, the Registry has also 
developed an extensive programme of research to augment our data with measures such as patient- and 
carer-reported outcome measures, from physical and psychological well-being and patient experiences of 
cancer services, through employment issues, supportive care needs and financial problems [101, 102]. Drawing 
on our database of over 100,000 cancer survivors, we can examine these issues in large, representative 
population samples. This research continues to give us valuable insights into patient experiences and has 
allowed us to develop better methods of assessing the quality of service which patients receive. While patients 
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are generally happy with their quality of care, we have identified a number of remediable shortcomings, 
particularly in the areas of communication and information. 
As noted throughout this report, projections of cancer cases based on existing trends in incidence are limited 
in their ability to predict the future cancer burden. More sophisticated methods, which can model trends in 
risk factors and attempt to predict the impact of measures such as programmes of prevention and screening, 
may be more useful, particularly in informing choices between different interventions such as prevention and 
screening. However, the overall conclusions from these projections are clear. Although we cannot modify the 
effects of demographic change, the majority of cancer risk is due to a small number of well-understood and 
potentially modifiable behaviours—UV exposure, smoking, alcohol consumption, diet and exercise. The 
majority of HPV infection is also now preventable, although other risk factors, such as hormonal and 
reproductive factors and Helicobacter pylori infection, are less amenable to change.  Many of these risk factors 
are also implicated in the causation of cardiovascular and respiratory disease, and their reduction through 
programmes of prevention must be a high priority for health policy. Detailed and comprehensive information 
on risk factor prevalence and its distribution in the population is essential to target and monitor preventive 
programmes.  Such information is patchy, episodic and lacking in detail in Ireland at present, a situation which 
needs to be addressed. 
Obviously, reports such as this are dependent on accurate and comprehensive cancer registration. The 
National Cancer Registry has operated in Ireland since 1994 with the full cooperation of all health service 
providers and with the active assistance of histopathology laboratories, HIPE units and many others. In recent 
times, some hospitals have had to withdraw or reduce their level of assistance to us due to resource 
limitations, forcing us to partially suspend or restrict cancer registration in these hospitals. We hope that these 
restrictions will be temporary; we are working with some hospitals on ways of integrating our activities with 
other cancer data collection by the hospital, to reduce overlap and duplication. We look forward to continuing 
our productive partnership with all healthcare providers in Ireland, both public and private, in the future, and 
hope that the projections contained in this report will be of lasting value to them. 
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29. Appendix 
Projections of new cases and percentage increase in numbers by year, sex and 
cancer site 
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Table 29.1 Projected number of new cases: demographic and Nordpred projections 
 demographic projections Nordpred projections 
females 2015 2020 2025 2030 2035 2040 2015 2020 2025 2030 2035 2040 
all invasive 14322 16172 18202 20295 22368 24287 14602 17624 20647 23670 26693 29715 
all invasive excluding NMSC  10192 11471 12849 14233 15576 16787 10362 12225 14087 15950 17813 19676 
head and neck 139 183 204 225 245 264 165 214 262 310 358 406 
oesophagus 154 177 205 237 271 305 134 164 194 224 254 283 
stomach 221 253 291 333 378 423 196 219 242 264 287 310 
colon 818 937 1075 1226 1382 1529 802 947 1092 1237 1382 1526 
rectum 367 417 475 535 594 648 343 417 490 564 637 711 
hepatobiliary 161 185 213 246 281 315 163 196 228 260 293 325 
pancreas 275 316 366 423 482 540 263 322 381 440 498 557 
lung 1013 1161 1334 1515 1694 1862 1068 1307 1545 1784 2022 2260 
melanoma of skin 500 554 607 659 713 766 564 658 752 846 940 1034 
non-melanoma skin 4131 4701 5353 6062 6791 7500 4275 5474 6673 7872 9070 10269 
breast 3209 3577 3937 4252 4514 4701 3494 4024 4555 5085 5615 6146 
cervix 327 350 361 365 372 379 361 410 459 507 556 604 
corpus uteri 423 479 537 593 643 680 472 525 578 631 684 738 
ovary 407 459 515 569 619 662 392 416 439 462 485 509 
kidney 210 238 268 299 330 359 241 293 345 397 449 501 
bladder 157 180 207 237 270 302 145 156 166 176 186 196 
brain and CNS 170 188 209 229 249 267 175 200 224 248 272 297 
Hodgkin's lymphoma 57 59 62 64 67 69 53 57 60 64 68 72 
Non-Hodgkin's lymphoma 341 385 433 482 528 570 359 413 467 520 574 627 
leukaemia 225 251 282 314 347 379 226 258 290 322 354 386 
males 2015 2020 2025 2030 2035 2040 2015 2020 2025 2030 2035 2040 
all invasive 17008 19692 22658 25775 28855 31704 15916 19643 23370 27097 30824 34551 
all invasive excluding NMSC  11816 13635 15639 17734 19784 21655 10971 13252 15534 17815 20097 22378 
head and neck 436 494 555 615 668 708 462 542 621 700 779 858 
oesophagus 296 342 393 449 501 549 263 313 364 415 465 516 
stomach 399 467 542 621 699 773 339 387 435 483 531 579 
colon 1033 1210 1409 1620 1829 2030 974 1136 1297 1458 1620 1781 
rectum 653 755 868 984 1094 1194 567 651 734 818 901 985 
hepatobiliary 221 257 298 340 382 421 215 274 332 391 449 507 
pancreas 299 349 404 463 524 580 269 333 397 461 525 590 
lung 1477 1728 2012 2314 2610 2889 1232 1383 1534 1685 1836 1987 
melanoma of skin 398 452 508 565 622 674 441 533 625 716 808 900 
non-melanoma skin 5192 6057 7020 8041 9071 10049 5011 6502 7993 9483 10974 12465 
prostate 3541 4091 4687 5307 5908 6426 3303 5141 6980 8818 10657 12495 
kidney 372 425 481 537 589 633 383 456 528 600 673 745 
bladder 397 470 555 647 745 838 290 302 314 326 338 350 
brain and CNS 225 250 276 301 325 345 211 216 220 225 230 234 
Hodgkin's lymphoma 73 78 81 84 87 90 79 84 89 93 98 103 
Non-Hodgkin's lymphoma 416 471 529 586 639 688 411 455 499 542 586 630 
leukaemia 349 398 453 511 567 620 293 314 335 355 376 396 
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Table 29.2 Projected number of new cases: Hakulinen/Dyba models with 95% confidence limits 
 Hakulinen-Dyba projections±95% confidence limits 
females 2015 2020 2025 2030 2035 2040 
all invasive 14271±296 16155±323 18284±353 20461±385 22580±417 24548±450 
all invasive excluding NMSC  9768±529 10754±988 11785±1552 12702±2196 13397±2882 13676±3492 
head and neck 157±26 177±27 198±29 220±31 241±33 259±34 
oesophagus 154±29 167±33 183±40 201±49 218±59 233±70 
stomach 197±32 205±36 214±41 224±48 231±55 236±62 
colon 811±59 928±63 1066±69 1216±75 1370±81 1518±87 
rectum 367±44 413±53 465±66 519±82 572±101 620±123 
hepatobiliary 157±26 179±27 205±29 235±32 267±34 298±36 
pancreas 260±36 296±43 340±54 390±68 442±85 492±106 
lung (model 1) 1108±75 1366±93 1682±116 2042±146 2429±182 2830±224 
lung (model 4) 916±63 1053±68 1210±74 1374±79 1538±85 1693±90 
melanoma of skin 620±57 757±70 911±85 1081±104 1269±126 1476±152 
non-melanoma skin 4848±215 6069±331 7565±488 9274±689 11143±938 13138±1232 
breast(model 1) 3631±153 4333±194 5117±247 5894±309 6639±379 7291±456 
breast(model 4) 3044±124 3383±132 3735±140 4042±148 4289±155 4472±160 
cervix 399±49 441±59 480±70 511±82 542±95 569±110 
corpus uteri 393±41 443±44 495±47 547±49 593±52 627±54 
ovary 377±45 403±53 430±63 452±75 467±87 474±99 
kidney 186±28 210±30 236±32 262±34 288±36 312±38 
bladder 148±28 153±31 160±36 166±41 171±47 173±52 
brain and CNS 165±26 183±28 203±29 222±31 241±32 258±33 
Hodgkin's lymphoma 67±17 71±17 73±18 77±18 81±19 84±19 
Non-Hodgkin's lymphoma 320±37 360±39 405±42 451±44 494±47 533±49 
leukaemia 197±33 210±38 224±46 239±55 252±65 263±75 
males 2015 2020 2025 2030 2035 2040 
all invasive 18880±341 21640±375 24858±416 28387±464 32026±519 35561±575 
all invasive excluding NMSC  12757±280 14605±309 16753±342 19097±381 21500±425 23822±471 
head and neck 448±49 498±59 551±73 603±90 649±108 684±128 
oesophagus 342±38 390±41 446±45 509±48 571±52 631±56 
stomach 393±46 410±52 428±61 445±71 457±81 463±92 
colon 1158±70 1331±76 1537±83 1764±90 1998±97 2230±104 
rectum 714±62 794±76 886±94 981±116 1069±143 1146±171 
hepatobiliary 224±31 256±34 295±36 336±39 380±43 423±46 
pancreas 338±38 387±41 446±45 511±48 581±53 650±57 
lung 1538±100 1677±124 1834±156 1992±195 2132±238 2245±283 
melanoma of skin 564±56 724±71 914±90 1137±114 1381±146 1645±184 
non-melanoma skin 7273±267 9331±418 11886±628 14943±910 18407±1281 22140±1730 
prostate 3436±205 3959±231 4560±262 5222±299 5907±342 6563±387 
kidney 353±39 373±40 389±41 397±42 403±42 410±43 
bladder 413±47 417±52 424±59 429±67 432±75 426±82 
brain and CNS 241±36 270±44 304±55 345±70 393±88 451±110 
Hodgkin's lymphoma 81±19 86±19 91±20 95±21 100±22 105±23 
Non-Hodgkin's lymphoma 424±43 477±46 537±49 599±52 658±55 713±59 
leukaemia 265±47 229±58 198±67 171±73 147±75 124±75 
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Table 29.3 Projected % increase in number of new cases: demographic, Hakulinen/Dyba and Nordpred  models 
 demographic projections Hakulinen/Dyba projections Nordpred projections 
females 2015 2020 2025 2030 2035 2040 2015 2020 2025 2030 2035 2040 2015 2020 2025 2030 2035 2040 
all invasive 9% 23% 38% 54% 70% 84% 8% 23% 39% 55% 71% 86% 11% 34% 57% 80% 102% 125% 
all invasive exc NMSC  10% 24% 39% 54% 68% 81% 5% 16% 27% 37% 45% 48% 12% 32% 52% 72% 92% 112% 
head and neck -22% 3% 15% 26% 38% 48% -12% -1% 11% 23% 35% 46% -7% 20% 47% 74% 101% 128% 
oesophagus 21% 39% 61% 86% 113% 140% 21% 32% 44% 58% 72% 84% 6% 29% 53% 76% 100% 123% 
stomach 24% 42% 63% 87% 112% 138% 11% 15% 20% 26% 30% 32% 10% 23% 36% 49% 61% 74% 
colon 16% 33% 53% 74% 97% 118% 15% 32% 52% 73% 95% 116% 14% 35% 55% 76% 97% 117% 
rectum 9% 23% 40% 58% 76% 92% 9% 22% 38% 54% 69% 83% 2% 23% 45% 67% 89% 110% 
hepatobiliary 23% 41% 63% 88% 115% 141% 20% 37% 57% 80% 104% 127% 25% 49% 74% 99% 123% 148% 
pancreas 34% 54% 79% 106% 135% 164% 27% 44% 66% 90% 115% 140% 28% 57% 86% 114% 143% 172% 
lung (model 1) 6% 21% 39% 58% 77% 95% 16% 43% 76% 113% 154% 196% 12% 37% 61% 86% 111% 136% 
lung (model 4) 6% 21% 39% 58% 77% 95% -4% 10% 26% 44% 61% 77% 12% 37% 61% 86% 111% 136% 
melanoma of skin -7% 3% 13% 23% 33% 43% 16% 41% 70% 102% 137% 175% 5% 23% 40% 58% 75% 93% 
non-melanoma skin 5% 20% 37% 55% 73% 91% 24% 55% 93% 137% 184% 235% 9% 40% 70% 101% 131% 162% 
breast(model 1) 11% 24% 36% 47% 56% 63% 26% 50% 77% 104% 130% 152% 21% 39% 58% 76% 94% 113% 
breast(model 4) 11% 24% 36% 47% 56% 63% 5% 17% 29% 40% 48% 55% 21% 39% 58% 76% 94% 113% 
cervix 2% 9% 13% 14% 16% 18% 24% 38% 49% 59% 69% 77% 13% 28% 43% 58% 73% 88% 
corpus uteri 9% 23% 38% 53% 66% 75% 1% 14% 28% 41% 53% 62% 22% 35% 49% 63% 76% 90% 
ovary 15% 30% 46% 61% 75% 87% 7% 14% 22% 28% 32% 34% 11% 18% 24% 31% 38% 44% 
kidney 6% 20% 35% 51% 67% 81% -6% 6% 19% 33% 46% 58% 22% 48% 74% 101% 127% 153% 
bladder 32% 51% 74% 99% 127% 154% 24% 29% 34% 39% 43% 45% 22% 31% 39% 48% 56% 65% 
brain and CNS -7% 3% 14% 25% 36% 46% -10% 0% 11% 22% 32% 41% -4% 9% 22% 36% 49% 62% 
Hodgkin's lymphoma -12% -9% -5% -1% 3% 7% 4% 9% 13% 18% 24% 30% -19% -13% -7% -1% 5% 11% 
Non-Hodgkin's lymphoma 8% 22% 37% 52% 66% 80% 1% 14% 28% 42% 56% 68% 13% 30% 47% 64% 81% 98% 
leukaemia 12% 25% 40% 56% 72% 88% -2% 4% 11% 19% 25% 31% 12% 28% 44% 60% 76% 92% 
males 2015 2020 2025 2030 2035 2040 2015 2020 2025 2030 2035 2040 2015 2020 2025 2030 2035 2040 
all invasive 11% 29% 48% 69% 89% 107% 23% 41% 63% 86% 109% 133% 4% 28% 53% 77% 102% 126% 
all invasive exc NMSC  13% 31% 50% 70% 90% 108% 22% 40% 61% 83% 106% 128% 5% 27% 49% 71% 93% 114% 
head and neck 6% 20% 35% 49% 62% 72% 9% 21% 34% 46% 58% 66% 12% 31% 51% 70% 89% 108% 
oesophagus 22% 41% 62% 85% 106% 126% 41% 61% 84% 109% 135% 160% 8% 29% 50% 71% 91% 112% 
stomach 9% 28% 49% 71% 92% 112% 8% 13% 18% 22% 26% 27% -7% 6% 19% 33% 46% 59% 
colon 19% 39% 62% 86% 110% 133% 33% 53% 76% 102% 129% 156% 12% 30% 49% 67% 86% 104% 
rectum 17% 35% 56% 76% 96% 114% 28% 42% 59% 76% 92% 105% 2% 17% 32% 47% 62% 77% 
hepatobiliary 11% 29% 50% 71% 92% 111% 13% 29% 48% 69% 91% 113% 8% 38% 67% 96% 126% 155% 
pancreas 16% 35% 57% 79% 103% 125% 31% 50% 73% 98% 125% 152% 4% 29% 54% 79% 104% 129% 
lung 13% 32% 54% 77% 100% 121% 18% 28% 40% 52% 63% 72% -6% 6% 17% 29% 40% 52% 
melanoma of skin 3% 17% 32% 47% 62% 75% 46% 88% 138% 195% 259% 327% 15% 38% 62% 86% 110% 134% 
non-melanoma skin 7% 25% 44% 65% 87% 107% 50% 92% 145% 208% 279% 356% 3% 34% 64% 95% 126% 157% 
prostate 10% 27% 45% 65% 83% 99% 7% 23% 42% 62% 83% 104% 3% 60% 117% 174% 231% 288% 
kidney 12% 28% 45% 62% 77% 91% 6% 12% 17% 20% 21% 24% 15% 37% 59% 81% 103% 124% 
bladder 24% 47% 73% 102% 133% 162% 29% 30% 32% 34% 35% 33% -10% -6% -2% 2% 6% 9% 
brain and CNS 24% 38% 52% 66% 80% 91% 33% 49% 68% 90% 117% 149% 17% 19% 22% 24% 27% 30% 
Hodgkin's lymphoma 1% 7% 11% 15% 19% 23% 11% 18% 24% 31% 37% 44% 8% 15% 21% 28% 35% 41% 
Non-Hodgkin's lymphoma 7% 21% 36% 50% 64% 76% 9% 22% 38% 54% 69% 83% 5% 17% 28% 39% 50% 62% 
leukaemia 22% 39% 59% 79% 98% 117% -7% -20% -31% -40% -49% -57% 3% 10% 17% 24% 31% 39% 
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